<SEC-DOCUMENT>0001193125-25-278392.txt : 20251113
<SEC-HEADER>0001193125-25-278392.hdr.sgml : 20251113
<ACCEPTANCE-DATETIME>20251112205533
ACCESSION NUMBER:		0001193125-25-278392
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20251112
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251113
DATE AS OF CHANGE:		20251112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eledon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001404281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36620
		FILM NUMBER:		251475081

	BUSINESS ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612
		BUSINESS PHONE:		949-238-8090

	MAIL ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Novus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tokai Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070622
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d28785d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:eldn="http://www.eledon.com/20251112" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2025-11-12_to_2025-11-12">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-312">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-11-12_to_2025-11-12">0001404281</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="eldn-20251112.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-11-12_to_2025-11-12"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-12</xbrli:startDate> <xbrli:endDate>2025-11-12</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-323">8-K</ix:nonNumeric></span></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-11-12_to_2025-11-12" format="ixt:datemonthdayyearen" id="ixv-324">November&#160;12, 2025</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-325">Eledon Pharmaceuticals, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-11-12_to_2025-11-12" format="ixt-sec:stateprovnameen" id="ixv-326">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-327">001-36620</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-328">20-1000967</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Commission<br/>File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-329">19800 MacArthur Blvd.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-330">Suite 250</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-331">Irvine</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-11-12_to_2025-11-12" format="ixt-sec:stateprovnameen" id="ixv-332">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-333">92612</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area <span style="white-space:nowrap">Code:&#160;<ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-334">(949)</ix:nonNumeric>&#160;<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-335">238-8090</ix:nonNumeric></span></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-11-12_to_2025-11-12" format="ixt-sec:boolballotbox" id="ixv-336">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-11-12_to_2025-11-12" format="ixt-sec:boolballotbox" id="ixv-337">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-11-12_to_2025-11-12" format="ixt-sec:boolballotbox" id="ixv-338">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-11-12_to_2025-11-12" format="ixt-sec:boolballotbox" id="ixv-339">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><br/>Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-340">Common Stock, $0.001 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-341">ELDN</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">Nasdaq Capital Market</span> </td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-11-12_to_2025-11-12" format="ixt-sec:boolballotbox" id="ixv-342">&#9744;</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;12, 2025, Eledon Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Leerink Partners, LLC, as representative of the several underwriters named therein (the &#8220;Underwriters&#8221;), in connection with the underwritten public offering and sale by the Company (the &#8220;Offering&#8221;) of 15,152,485 shares (the &#8220;Firm Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;) at a public offering price of $1.65 per share (the &#8220;Common Stock Purchase Price&#8221;), and <span style="white-space:nowrap">pre-funded</span> warrants (the <span style="white-space:nowrap">&#8220;Pre-Funded</span> Warrants&#8221;) at a public offering price of $1.649 per <span style="white-space:nowrap">Pre-Funded</span> Warrant, which are exercisable to purchase up to 15,151,515 shares of Common Stock at an exercise price of $0.001 per share. In addition, pursuant to the Underwriting Agreement, the Company granted the Underwriters an option (the &#8220;Option&#8221;), exercisable for 30 days, to purchase up to 4,545,600 additional shares of Common Stock (the &#8220;Option Shares&#8221;, and together with the Firm Shares, the &#8220;Shares&#8221;) at the Common Stock Purchase Price less the underwriting discounts and commissions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering is expected to close on or about November&#160;13, 2025, subject to the satisfaction of customary closing conditions. The estimated net proceeds to the Company from the Offering, after deducting the Underwriters&#8217; discounts and commissions and the Company&#8217;s estimated offering expenses, are approximately $46.5&#160;million (which may increase to approximately $53.6&#160;million if the Underwriters exercise the Option in full). The Company currently plans to use the net proceeds from the Offering to support the continued clinical development of its product candidates and advance its pipeline programs as well as for general corporate purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering is being made pursuant to the Company&#8217;s registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-282260),</span> previously filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on September&#160;20, 2024 and declared effective by the SEC on October&#160;2, 2024 and a prospectus supplement relating to the Offering that has been filed with the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations and warranties and also contains customary indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting&#160;Agreement, the Company and certain of its executive officers and directors have entered into <span style="white-space:nowrap">&#8220;lock-up&#8221;</span> agreements with the Underwriters&#160;that, subject to certain exceptions, generally prohibit the sale, transfer, or other disposition of securities of the Company for a period of 60 days from November&#160;12, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of the Underwriting&#160;Agreement, including the representations and warranties contained therein, are not for the benefit of any party other than the parties to such agreements and are not intended as documents for investors and the public to obtain factual information about the current state of affairs of the parties to those documents and agreements. Rather, investors and the public should look to other disclosures contained in the Company&#8217;s filings with the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of <span style="white-space:nowrap">Pre-Funded</span> Warrants (together with its affiliates) may not exercise any portion of a <span style="white-space:nowrap">Pre-Funded</span> Warrant to the extent that, after giving effect to such exercise, the holder (together with the holder&#8217;s affiliates, and any other persons acting as a group together with the holder or any of the holder&#8217;s affiliates) would beneficially own in excess of 4.99% (or, at the holder&#8217;s option upon issuance, 9.99%) of the number of shares of our common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable upon exercise of such warrant. The beneficial ownership limitation may be increased at the option of the holder upon 61 days&#8217; prior notice to the Company, provided, however, that, to the extent required by applicable Nasdaq Marketplace Rules, the beneficial ownership limitation may not exceed 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of such <span style="white-space:nowrap">Pre-Funded</span> Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms of the Underwriting&#160;Agreement and <span style="white-space:nowrap">Pre-Funded</span> Warrants is subject to, and qualified in its entirety by reference to, the full text of the Underwriting Agreement and the form of <span style="white-space:nowrap">Pre-Funded</span> Warrant, which are filed as Exhibits 1.1 and 4.1, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K</span> and are incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the legal opinion and consent of O&#8217;Melveny&#160;&amp; Myers LLP relating to the Shares and <span style="white-space:nowrap">Pre-Funded</span> Warrants is attached as Exhibit 5.1 hereto. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d28785dex11.htm">Underwriting Agreement, dated November&#160;12, 2025, by and between Eledon Pharmaceuticals, Inc. and Leerink Partners LLC, as representative of the several underwriters named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d28785dex41.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d28785dex51.htm">Legal Opinion of O&#8217;Melveny&#160;&amp; Myers LLP, dated November&#160;12, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Eledon Pharmaceuticals, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: November&#160;12, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David-Alexandre C. Gros, M.D.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">David-Alexandre C. Gros, M.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d28785dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Eledon Pharmaceuticals, Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a
Delaware corporation) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15,152,485 Shares of Common Stock </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">Pre-Funded&nbsp;Warrants</FONT> to Purchase up to 15,151,515 Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">November&nbsp;12, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Representative of the several Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink
Partners LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53 State Street, 40th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02109
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Eledon
Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<U>Company</U>&#8221;), confirms its agreement with Leerink Partners LLC&nbsp;(&#8220;<U>Leerink Partners</U>&#8221;), and each of the other Underwriters named in
<U>Schedule</U><U></U><U>&nbsp;A</U> hereto (collectively, the &#8220;<U>Underwriters</U>,&#8221; which term shall also include any underwriter substituted as hereinafter provided in Section&nbsp;10 hereof), for which Leerink Partners is acting as
representative (in such capacity, the &#8220;<U>Representative</U>&#8221;), with respect to (i)&nbsp;the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares (the &#8220;Firm
<U>Shares</U>&#8221;) of common stock, par value $0.001 per share, of the Company (&#8220;<U>Common Stock</U>&#8221;), and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, substantially in the form of <U>Exhibit B</U> hereto, to purchase
shares of Common Stock (the &#8220;<U><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</U>&#8221;, and together with the Firm Shares, the &#8220;<U>Initial Securities</U>&#8221;)&nbsp;set forth in <U>Schedule</U><U></U><U>&nbsp;A</U>
hereto, and (ii)&nbsp;the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section&nbsp;2(b) hereof to purchase all or any part of 4,545,600 additional shares of Common Stock (the
&#8220;<U>Option Shares</U>&#8221; and, together with the Initial Securities, the &#8220;<U>Securities</U>&#8221;). The Firm Shares and Option Shares are herein called, collectively, the &#8220;<U>Shares</U>.&#8221; The shares of Common Stock
issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are hereinafter referred to as the &#8220;<U>Warrant Shares</U>.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company understands that the Underwriters propose to make a public offering of the Securities as soon as the Representative deems
advisable after this Underwriting Agreement (this &#8220;<U>Agreement</U>&#8221;) has been executed and delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has filed
with the Securities and Exchange Commission (the &#8220;<U>Commission</U>&#8221;) a shelf registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-282260),</FONT> including a
prospectus (the &#8220;<U>Base Prospectus</U>&#8221;), covering the offering and sale of certain securities, including the Securities, under the Securities Act of 1933, as amended (the &#8220;<U>1933 Act</U>&#8221;) and the rules and regulations of
the Commission promulgated thereunder (the &#8220;<U>1933 Act Regulations</U>&#8221;), which shelf registration statement was declared effective on October&nbsp;2, 2024. Such registration statement, as of any time, means such registration statement
as amended by any post-effective amendments thereto to such time, including the exhibits and any schedules thereto at such time, the documents incorporated or deemed to be incorporated by reference therein at such time
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule 430B under the
1933 Act Regulations (&#8220;<U>Rule 430B</U>&#8221;), is referred to herein as the &#8220;<U>Registration Statement</U>;&#8221; provided, however, that the &#8220;Registration Statement&#8221; without reference to a time means such registration
statement as amended by any post-effective amendments thereto as of the time of the first contract of sale for the Securities, which time shall be considered the &#8220;new effective date&#8221; of such registration statement with respect to the
Securities within the meaning of paragraph (f)(2) of Rule 430B, including the exhibits and schedules thereto as of such time, the documents incorporated or deemed incorporated by reference therein at such time pursuant to Item 12 of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to the Rule 430B. Any registration statement filed pursuant to Rule 462(b) of the 1933 Act Regulations is
herein called the &#8220;<U>Rule 462(b) Registration Statement</U>&#8221; and, after such filing, the term &#8220;Registration Statement&#8221; shall include the Rule 462(b) Registration Statement. Each preliminary prospectus supplement used in
connection with the offering of the Securities, if any, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act, together with
the Base Prospectus, are collectively referred to herein as a &#8220;preliminary prospectus.&#8221; Promptly after the execution and delivery of this Agreement, the Company will prepare and file a final prospectus supplement to the Base Prospectus
relating to the Securities in accordance with the provisions of Rule 424(b) under the 1933 Act Regulations (&#8220;<U>Rule 424(b)</U>&#8221;). The final prospectus supplement, in the form first furnished or made available to the Underwriters for use
in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act, together with the
Base Prospectus, are collectively referred to herein as the &#8220;Prospectus.&#8221; For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment or supplement to any of
the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (or any successor system) (&#8220;<U>EDGAR</U>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Applicable Time&#8221; means 7:00 A.M., New York City time, on November&nbsp;12, 2025 or such other time as agreed by
the Company and the Representative. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;General Disclosure Package&#8221; means any Issuer General Use Free Writing
Prospectuses issued at or prior to the Applicable Time, the most recent preliminary prospectus (including any documents incorporated therein by reference) that is distributed to investors prior to the Applicable Time and the information included on
<U>Schedule</U><U></U><U>&nbsp;B</U><U><FONT STYLE="white-space:nowrap">-1</FONT></U> hereto, all considered together. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Issuer Free Writing Prospectus&#8221; means any &#8220;issuer free writing prospectus,&#8221; as defined in Rule 433 of
the 1933 Act Regulations (&#8220;<U>Rule 433</U>&#8221;), including without limitation any &#8220;free writing prospectus&#8221; (as defined in Rule 405 of the 1933 Act Regulations (&#8220;<U>Rule 405</U>&#8221;)) relating to the Securities that is
(i)&nbsp;required to be filed with the Commission by the Company, (ii)&nbsp;a &#8220;road show for an offering that is a written communication&#8221; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission,
or (iii)&nbsp;exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed
with the Commission or, if not required to be filed, in the form retained in the Company&#8217;s records pursuant to Rule 433(g). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Issuer General Use Free Writing Prospectus&#8221; means any Issuer Free Writing Prospectus that is intended for general
distribution to prospective investors (other than a &#8220;<I>bona fide</I> electronic road show,&#8221; as defined in Rule 433 (a &#8220;<U>Bona Fide Electronic Road Show</U>&#8221;)), as evidenced by its being specified in
<U>Schedule</U><U></U><U>&nbsp;B</U><U><FONT STYLE="white-space:nowrap">-2</FONT></U> hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Issuer Limited Use Free Writing Prospectus&#8221; means any Issuer
Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;Testing-the-Waters</FONT></FONT> Communication&#8221;
means any oral or written communication with potential investors undertaken in reliance on Section&nbsp;5(d) of the 1933 Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication&#8221; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the 1933 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to financial statements and schedules and other information which is &#8220;contained,&#8221;
&#8220;included&#8221; or &#8220;stated&#8221; (or other references of like import) in the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include all such financial statements and schedules and other
information incorporated or deemed incorporated by reference in the Registration Statement, any preliminary prospectus or the Prospectus, as the case may be, prior to the execution and delivery of this Agreement; and all references in this Agreement
to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder (collectively, the &#8220;<U>1934 Act</U>&#8221;), incorporated or deemed to be incorporated by reference in the Registration Statement, such preliminary prospectus or the Prospectus, as the case may be, at or after the
execution and delivery of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Representations and Warranties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Representations and Warranties by the Company</I>. The Company represents and warrants to each Underwriter as of the date hereof, the
Applicable Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with each Underwriter, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Registration Statement</U><U> and Prospectuses</U>. The Company meets the requirements for use of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act. Each of the Registration Statement and any amendment thereto has become effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment thereto has been issued by the Commission under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued by the Commission and no proceedings for any of those
purposes have been instituted by the Commission or are pending or, to the Company&#8217;s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Registration Statement and any post-effective amendment thereto, at the time of its effectiveness and at each
deemed effective date with respect to the Underwriters pursuant to Rule 430B(f)(2) under the 1933 Act Regulations, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus, the
Prospectus and any amendment or supplement thereto, at the time each was filed with the Commission, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus delivered to the
Underwriters for use in connection with the offering and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The documents incorporated or deemed to be incorporated by reference in the
Registration Statement and the Prospectus, when they became effective or at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the 1934 Act and the rules and
regulations of the Commission under the 1934 Act (the &#8220;<U>1934 Act Regulations</U>&#8221;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registration
Statement, any preliminary prospectus and the Prospectus, and the filing of the Registration Statement, any preliminary prospectus and the Prospectus with the Commission have been duly authorized by and on behalf of the Company, and the Registration
Statement has been duly executed pursuant to such authorization. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Accurate Disclosure</U>. Neither the Registration
Statement nor any amendment thereto, at its effective time, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated therein or necessary to make the
statements therein not misleading. As of the Applicable Time, none of (A)&nbsp;the General Disclosure Package, nor (B)&nbsp;any individual Issuer Limited Use Free Writing Prospectus, when considered together with the General Disclosure Package,
included, and at the Closing Time or at any Date of Delivery, will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b)
or at the Closing Time or at any Date of Delivery, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading. The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, at the time the Registration
Statement became effective or when such documents incorporated by reference were filed with the Commission, as the case may be, when read together with the other information in the Registration Statement, the General Disclosure Package or the
Prospectus, as the case may be, did not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations and warranties in this subsection shall not apply to statements in or omissions from the Registration
Statement (or any amendment thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto, including any prospectus wrapper) made in reliance upon and in conformity with written information furnished to the
Company by any Underwriter through the Representative expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the information in the first paragraph under the heading &#8220;Underwriting&#8212;Discounts
and Commissions&#8221; and the information in the second, third, and fourth paragraphs under the heading &#8220;Underwriting&#8212;Price Stabilization, Short Positions and Penalty Bids&#8221; in each case contained in the Prospectus (collectively,
the &#8220;<U>Underwriter Information</U>&#8221;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Issuer Free Writing Prospectuses</U>. No Issuer Free Writing
Prospectus conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein, and any preliminary or other prospectus deemed to be a part thereof that
has not been superseded or modified. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus made in reliance upon and in conformity with the Underwriter Information. No filing of any &#8220;road
show&#8221; (as defined in Rule 433(h)) is required in connection with the offering of the Securities. Any Issuer Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the 1933 Act has been, or will be, filed
with the Commission in accordance with the requirements of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
1933 Act and the 1933 Act Regulations. Each Issuer Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the 1933 Act or that was prepared by
or behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Except for the Issuer Free Writing Prospectuses, if any, identified in
<U>Schedule <FONT STYLE="white-space:nowrap">B-2</FONT></U> hereto, and electronic road shows, if any, each furnished to the Representative before first use, the Company has not prepared, used or referred to, and will not, without the prior consent
of the Representative, prepare, use or refer to, any Issuer Free Writing Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials. The Company (A)&nbsp;has not engaged in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, (B)&nbsp;has not authorized anyone to engage in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications, and (C)&nbsp;has not distributed any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)
<U>Company Not Ineligible Issuer</U>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or another offering participant made a <I>bona fide</I> offer (within
the meaning of Rule 164(h)(2) of the 1933 Act Regulations) of the Securities and at the date hereof, the Company was not and is not an &#8220;ineligible issuer,&#8221; as defined in Rule 405, without taking account of any determination by the
Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)
<U>Statistical and Market-Related Data</U>. All statistical, demographic and market-related data included in the Registration Statement, the General Disclosure Package or the Prospectus are based on or derived from sources that the Company believes,
after reasonable inquiry, to be reliable and accurate. To the extent required, the Company has obtained the written consent for the use of such data from such sources. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) <U>Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</U>. The
Company has established and maintains disclosure controls and procedures (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the 1934 Act), which (i)&nbsp;are designed to
ensure that material information relating to the Company, including its consolidated Subsidiaries, is made known to the Company&#8217;s principal executive officer and its principal financial officer by others within those entities, particularly
during the periods in which the periodic reports required under the 1934 Act are being prepared; (ii)&nbsp;have been evaluated by management of the Company for effectiveness as of the end of the Company&#8217;s most recent fiscal quarter; and
(iii)&nbsp;except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, are effective in all material respects to perform the functions for which they were established. Except as disclosed in the Registration
Statement, the General Disclosure Package and the Prospectus, since the end of the Company&#8217;s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#8217;s internal control over
financial reporting (whether or not remediated) and no change in the Company&#8217;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over
financial reporting. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any change in its internal control over financial reporting that has occurred during its most
recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) <U>This Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) <U>Authorization and Description of Securities</U>. The Securities to
be purchased by the Underwriters from the Company have been duly authorized for issuance and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against payment of the
consideration set forth herein, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> and the issuance and sale of the Securities is not subject to any preemptive rights, rights of first refusal or other
similar rights to subscribe for or purchase the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>No Applicable Registration or Other Similar Rights</U>.
There are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been
duly waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) <U>No Material Adverse Effect</U>. Except as otherwise disclosed in the Registration Statement, the
General Disclosure Package and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the General Disclosure Package and the Prospectus: (i)&nbsp;there has been no material adverse change,
or any development that could reasonably be expected to result in a material adverse change, in (A)&nbsp;the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or
prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its Subsidiaries, considered as one entity or (B)&nbsp;the ability of the Company to consummate the transactions contemplated by this
Agreement or perform its obligations hereunder (any such change being referred to herein as a &#8220;<U>Material Adverse Effect</U>&#8221;); (ii) the Company and its Subsidiaries, considered as one entity, have not incurred any material liability or
obligation, indirect, direct or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike,
labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its Subsidiaries, considered as one entity, and have not entered into any material transactions not in the
ordinary course of business; and (iii)&nbsp;there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its Subsidiaries and there has been no dividend or
distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other Subsidiaries, by any of the Company&#8217;s Subsidiaries on any class of capital stock, or any repurchase or redemption by the
Company or any of its Subsidiaries of any class of capital stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) <U>Independent Accountants</U>. The accountants
who certified the financial statements and supporting schedules included in the Registration Statement, the General Disclosure Package and the Prospectus are independent public accountants as required by the 1933 Act, the 1933 Act Regulations, the
1934 Act, the 1934 Act Regulations and the Public Company Accounting Oversight Board (United States). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) <U>Financial
Statements</U>. The financial statements filed with the Commission as a part of the Registration Statement, the General Disclosure Package and the Prospectus present fairly the consolidated financial position of the Company and its Subsidiaries as
of the dates indicated and the results of their operations, changes in stockholders&#8217; equity and cash flows for the periods specified. The supporting schedules included in the Registration Statement present fairly the information required to be
stated therein. Such financial statements and supporting schedules have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;<U>GAAP</U>&#8221;) applied on a consistent basis throughout the periods involved, except
as may be expressly stated in the related notes thereto. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto. No other financial statements or supporting schedules are required
to be included in the Registration Statement, the General Disclosure Package or the Prospectus. To the Company&#8217;s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has
failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the
Commission as a part of the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) <U>Company&#8217;s Accounting System</U>. The
Company and each of its Subsidiaries make and keep accurate books and records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with
management&#8217;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP as applied in the United States and to maintain accountability for assets;
(iii)&nbsp;access to assets is permitted only in accordance with management&#8217;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action
is taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for
in all material respects and is prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) <U>Incorporation and Good Standing of the Company</U>. The Company has been duly incorporated and is validly existing as a
corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the
General Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. The Company is duly qualified as a foreign corporation to transact
business and is in good standing in the State of California and each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so
qualified and in good standing would not be expected, individually or in the aggregate to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi) <U>Subsidiaries</U>. Each subsidiary of the Company (each, a &#8220;<U>Subsidiary</U>&#8221; and, collectively, the
&#8220;<U>Subsidiaries</U>&#8221;) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of
its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the
Prospectus. Each of the Subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which such qualification is required,
whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified and in good standing would not be expected, individually or in the aggregate to result in a Material Adverse Effect.
All of the issued and outstanding capital stock or other equity or ownership interests of each of the Subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through
subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. None of the outstanding capital stock or equity interest in any Subsidiary was issued in violation of preemptive or similar rights of any
security holder of such Subsidiary. The constitutive or organizational documents of each of the Subsidiaries comply in all material respects with the requirements of applicable laws of its jurisdiction of incorporation or organization and are in
full force and effect. The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the Subsidiaries listed in Exhibit 21.1 to the Company&#8217;s most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed with the Commission, except for any subsidiary that may be formed after the filing date of such Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii) <U>Capitalization and Other Capital Stock Matters</U>. The
authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement, the General Disclosure Package and the Prospectus under the caption &#8220;The Offering&#8221; and &#8220;Description of Capital
Stock&#8221; (other than for subsequent issuances, if any, pursuant to employee benefit plans described in the General Disclosure Package and the Prospectus, subsequent issuances, if any, pursuant to securities purchase agreements described in the
General Disclosure Package or the Prospectus or upon the conversion of outstanding preferred stock or the exercise of outstanding options or warrants, in each case described in the Registration Statement, the General Disclosure Package and the
Prospectus). The Common Stock and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants conforms in all material respects to the description thereof contained in the General Disclosure Package and the Prospectus. All of the issued and
outstanding Common Stock has been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants
have been duly authorized by the Company and, when executed and delivered by the Company, will be valid and binding agreements of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be
limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles. The Warrant Shares have been duly authorized and validly reserved
for issuance upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in a number sufficient to meet the current exercise requirements. The Warrant Shares, when issued and delivered upon exercise of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in accordance therewith, will be validly issued, fully paid and nonassessable, and the issuance of the Warrant Shares, is not subject to any preemptive or other similar rights to subscribe for or
purchase the Warrant Shares. No holder of Securities will be subject to personal liability by reason of being such a holder. None of the outstanding Common Stock was issued in violation of any preemptive rights, rights of first refusal or other
similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or
exchangeable or exercisable for, any capital stock of the Company or any of its Subsidiaries other than those described in the Registration Statement, the General Disclosure Package and the Prospectus. The descriptions of the Company&#8217;s stock
option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the Registration Statement, the General Disclosure Package and the Prospectus accurately and fairly presents the information
required to be shown with respect to such plans, arrangements, options and rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xviii) <U>Listing</U>. The Shares and
Warrant Shares have been approved for listing on the Nasdaq Capital Market, subject to notice of issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xix) <U><FONT
STYLE="white-space:nowrap">Non-Contravention</FONT> of Existing Instruments; No Further Authorizations or Approvals Required</U>. Neither the Company nor any of its Subsidiaries is in violation of its charter or
<FONT STYLE="white-space:nowrap">by-laws,</FONT> partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default)
(&#8220;<U>Default</U>&#8221;) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other
instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its Subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets
are subject </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
(each, an &#8220;<U>Existing Instrument</U>&#8221;), except for such Defaults as could not be expected, individually or in the aggregate, to result in a Material Adverse Effect. The
Company&#8217;s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and by the Registration Statement, the General Disclosure Package and the Prospectus and the issuance and sale of the
Securities (including the use of proceeds from the sale of the Securities as described in the Registration Statement, the General Disclosure Package and the Prospectus under the caption &#8220;Use of Proceeds&#8221;) (i) have been duly authorized by
all necessary corporate action and will not result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws,</FONT> partnership agreement or operating agreement or similar organizational documents, as applicable,
of the Company or any Subsidiary (ii)&nbsp;will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon
any property or assets of the Company or any of its Subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument and (iii)&nbsp;will not result in any violation of any law, administrative regulation or
administrative or court decree applicable to the Company or any of its Subsidiaries. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is
required for the Company&#8217;s execution, delivery and performance of this Agreement and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and consummation of the transactions contemplated hereby and by the Registration Statement,
the General Disclosure Package and the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the 1933 Act and such as may be required under applicable state securities or blue sky laws or
Financial Industry Regulatory Authority, Inc. (&#8220;<U>FINRA</U>&#8221;). As used herein, a &#8220;<U>Debt Repayment Triggering Event</U>&#8221; means any event or condition which gives, or with the giving of notice or lapse of time would give,
the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#8217;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of
its Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <U>No Material Actions or Proceedings</U>. Except as otherwise disclosed in the Prospectus, there
is no action, suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity (including, without limitation, any action, suit proceeding, inquiry or investigation before or brought by the U.S. Food and Drug
Administration (the &#8220;<U>FDA</U>&#8221;) or the European Medicines Agency (the &#8220;<U>EMA</U>&#8221;)) now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its Subsidiaries, which could be
expected, individually or in the aggregate, to result in a Material Adverse Effect. No material labor dispute with the employees of the Company or any of its subsidiaries, or with the employees of any principal supplier, manufacturer, customer or
contractor of the Company, exists or, to the knowledge of the Company, is threatened or imminent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxi) <U>Intellectual
Property Rights</U>. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, the Company and its Subsidiaries own, or have obtained valid and enforceable licenses for, the inventions, patent
applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement, the General Disclosure Package and the Prospectus as being owned or licensed by them or
which are necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively, &#8220;<U>Intellectual Property</U>&#8221;). To the Company&#8217;s knowledge: (i)&nbsp;there are no
third parties who have rights to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the General Disclosure Package and
the Prospectus as licensed to the Company or one or more of its Subsidiaries; and (ii)&nbsp;there is no infringement by third parties of any Intellectual Property. There is no pending or, to the Company&#8217;s knowledge, threatened action, suit,
proceeding or claim by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
others: (A)&nbsp;challenging the Company&#8217;s rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit,
proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or
(C)&nbsp;asserting that the Company or any of its Subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement, the General Disclosure Package or the Prospectus
as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such
action, suit, proceeding or claim. The Company and its Subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any Subsidiary, and all such
agreements are in full force and effect. The product candidates described in the Registration Statement, the General Disclosure Package and the Prospectus as under development by the Company or any Subsidiary fall within the scope of the claims of
one or more patents owned by, or exclusively licensed to, the Company or any Subsidiary. The Company and its Subsidiaries have taken reasonable steps to protect, maintain and safeguard their Intellectual Property, including the execution of
appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and no employee of the Company is in or has been in material violation of any term of any employment contract,
patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement, or any restrictive covenant
to or with a former employer where the basis of such violation relates to such employee&#8217;s employment with the Company. The duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the
United States patents and patent applications included in the Intellectual Property have been complied with in all material respects; and in all foreign offices having similar requirements, all such requirements have been complied with in all
material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxii) <U>All Necessary Permits, etc</U>. Except as otherwise disclosed in the Prospectus, the Company
and each Subsidiary possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the
Registration Statement, the General Disclosure or the Prospectus (&#8220;<U>Permits</U>&#8221;), except for such certificates, authorizations or permits whose failure to obtain would not be expected, individually or in the aggregate, to result in a
Material Adverse Effect. Neither the Company nor any of its Subsidiaries is in violation of, or in default under, any of the Permits (except for such violations or defaults that would not be expected, individually or in the aggregate to result in a
Material Adverse Effect) or has received any notice of proceedings relating to the revocation or modification of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with, any such certificate, authorization or permit, which, if the subject of
an unfavorable decision, ruling or finding, would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiii) <U>Title to Properties</U>. Except as otherwise disclosed in the Prospectus, the Company and its Subsidiaries has good
and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section&nbsp;2(a)(iii) above (or elsewhere in the Registration Statement, the General Disclosure Package or
the Prospectus, in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except such as do not materially and adversely affect the value of such property and do not materially
interfere with the use made or proposed to be made of such property by the Company or any of its Subsidiaries. The real property, improvements, equipment and personal property held under lease by the Company or of its Subsidiary are held under valid
and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such Subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiv) <U>Tax Law Compliance</U>. The Company and its Subsidiaries have
filed all necessary federal, state and foreign income and franchise tax returns or have properly requested extensions thereof and have paid all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine
or penalty levied against any of them except as may be being contested in good faith and by appropriate proceedings, and except for such exceptions as could not be expected, individually or in the aggregate to result in a Material Adverse Effect.
The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section&nbsp;2(a)(iii) above in respect of all federal, state and foreign income and franchise taxes for all periods as to which the
tax liability of the Company or any of its Subsidiaries has not been finally determined. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxv) <U>Investment Company
Act</U>. The Company is not required, and upon the issuance and sale of the Securities as herein contemplated and the application of the proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus
will not be required, to register as an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended (the &#8220;<U>1940 Act</U>&#8221;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvi) <U>Insurance</U>. Except as otherwise disclosed in the Prospectus, each of the Company and its Subsidiaries are insured
by recognized, financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as, in the reasonable judgment of the Company, are generally deemed adequate and customary for their
businesses including, but not limited to, policies covering real and personal property owned or leased by the Company and its Subsidiaries against theft, damage, destruction, acts of vandalism and policies covering the Company and its Subsidiaries
for product liability claims and clinical trial liability claims. The Company has no reason to believe that it or any of its Subsidiaries will not be able (i)&nbsp;to renew its existing insurance coverage as and when such policies expire or
(ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that could not be expected to result in a Material Adverse Effect. Neither the Company nor
any of its Subsidiaries has been denied any insurance coverage which it has sought or for which it has applied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvii)
<U>No Price Stabilization or Manipulation; Compliance with Regulation</U><U></U><U>&nbsp;M</U>. Neither the Company nor any of its Subsidiaries has taken, directly or indirectly, any action designed to or that might cause or result in stabilization
or manipulation of the price of the Common Stock or of any &#8220;reference security&#8221; (as defined in Rule 100 of Regulation M under the 1934 Act (&#8220;<U>Regulation M</U>&#8221;)) with respect to the Common Stock, whether to facilitate the
sale or resale of the Securities or otherwise, and has taken no action which would directly or indirectly violate Regulation&nbsp;M. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxviii) <U>Compliance with Environmental Laws</U>. Except as described in the Prospectus and except as could not be expected,
individually or in the aggregate, to result in a Material Adverse Effect; (i)&nbsp;neither the Company nor any of its Subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or
rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without
limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes,
toxic substances, hazardous </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
substances, petroleum or petroleum products (collectively, &#8220;<U>Hazardous Materials</U>&#8221;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials (collectively, &#8220;<U>Environmental Laws</U>&#8221;), (ii) the Company and its Subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in
compliance with their requirements, (iii)&nbsp;there are no pending or, to the knowledge of the Company, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation,
investigation or proceedings relating to any Environmental Law against the Company or any of its Subsidiaries and (iv)&nbsp;there are no events or circumstances that might reasonably be expected to form the basis of an order for <FONT
STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its Subsidiaries relating to Hazardous Materials or any
Environmental Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxix) <U>Periodic Review of Costs of Environmental Compliance</U>. In the ordinary course of its
business, the Company conducts a periodic review of the effect of Environmental Laws on the business, operations and properties of the Company and its Subsidiaries, in the course of which it identifies and evaluates associated costs and liabilities
(including, without limitation, any capital or operating expenditures required for <FONT STYLE="white-space:nowrap">clean-up,</FONT> closure of properties or compliance with Environmental Laws or any permit, license or approval, any related
constraints on operating activities and any potential liabilities to third parties). No facts or circumstances have come to the Company&#8217;s attention that could result in costs or liabilities that could be expected, individually or in the
aggregate, to result in a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxx) <U>ERISA Compliance</U>. Except as otherwise disclosed in the
Prospectus, the Company and its Subsidiaries and any &#8220;employee benefit plan&#8221; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively,
&#8220;<U>ERISA</U>&#8221;)) established or maintained by the Company, its Subsidiaries or their &#8220;ERISA Affiliates&#8221; (as defined below) are in compliance in all material respects with ERISA. &#8220;<U>ERISA Affiliate</U>&#8221; means,
with respect to the Company or any of its subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations
thereunder (the &#8220;<U>Code</U>&#8221;) of which the Company or such Subsidiary is a member. No &#8220;reportable event&#8221; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any &#8220;employee benefit
plan&#8221; established or maintained by the Company, its Subsidiaries or any of their ERISA Affiliates that could reasonably be expected to result in material liability to the Company. No &#8220;employee benefit plan&#8221; established or
maintained by the Company, its Subsidiaries or any of their ERISA Affiliates, if such &#8220;employee benefit plan&#8221; were terminated, would have any &#8220;amount of unfunded benefit liabilities&#8221; (as defined under ERISA). Neither the
Company, its Subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i)&nbsp;Title IV of ERISA with respect to termination of, or withdrawal from, any &#8220;employee benefit plan&#8221; or
(ii)&nbsp;Sections 412, 4971, 4975 or 4980B of the Code. Each &#8220;employee benefit plan&#8221; established or maintained by the Company, its Subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section&nbsp;401(a)
of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would be reasonably expected to cause the loss of such qualification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxi) <U>Brokers</U>. Except as disclosed in the General Disclosure Package, there is no broker, finder or other party that is
entitled to receive from the Company any brokerage or finder&#8217;s fee or other fee or commission as a result of any transactions contemplated by this Agreement and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxii) <U>Anti-Corruption and Anti-Bribery Laws</U>. Neither the Company
nor any of its Subsidiaries nor any director, officer, or employee of the Company or any of its Subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its Subsidiaries has,
in the course of its actions for, or on behalf of, the Company or any of its Subsidiaries (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made
or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or public
international organization, or any political party, party official, or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the
&#8220;<U>FCPA</U>&#8221;), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence
payment, kickback or other unlawful payment or benefit. The Company and its Subsidiaries and, to the knowledge of the Company, the Company&#8217;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted
and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxiii) <U>Money Laundering Laws</U>. The operations of the Company and its Subsidiaries are, and have been conducted at all
times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and
regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#8220;<U>Money Laundering Laws</U>&#8221;) and no action, suit or
proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxiv) <U>Clinical Data and Regulatory Compliance</U>. The preclinical tests and clinical trials, and other studies
(collectively, &#8220;<U>studies</U>&#8221;) that are described in, or the results of which are referred to in, the Registration Statement, the General Disclosure Package or the Prospectus were and, if still pending, are being conducted in all
material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete
in all material respects and fairly presents the data derived from such studies, and the Company and its Subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results
described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus; the Company and its Subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug
Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively,
the &#8220;<U>Regulatory Agencies</U>&#8221;); neither the Company nor any of its Subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials
that are described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus; and the Company and its Subsidiaries have each operated and currently are in compliance in all material respects with all applicable
rules, regulations and policies of the Regulatory Agencies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxv) <U>Compliance with Health Care Laws</U>. The Company and its
Subsidiaries are, and at all times have been, in compliance with all Health Care Laws. For purposes of this Agreement, &#8220;<U>Health Care Laws</U>&#8221; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et
seq.), the Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the
Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal false statements law (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under HIPAA (as defined below) (42 U.S.C. Section&nbsp;1320d et seq.), the Stark Law (42 U.S.C.
Section&nbsp;1395nn), the civil monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusion law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments
Sunshine Act (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and applicable laws governing government funded or sponsored healthcare programs; (iii)&nbsp;HIPAA, as amended by the Health Information Technology for Economic
and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation
requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vi)&nbsp;all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its Subsidiaries, and
(vii)&nbsp;the directives and regulations promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof. Neither the Company nor any of its Subsidiaries has received written notice of any
claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of
any Health Care Laws nor, to the Company&#8217;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. The Company and its Subsidiaries have filed, maintained or
submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its Subsidiaries is a party to any
corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its Subsidiaries nor any of their
respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental
inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxvi) <U>Sanctions</U>. Neither the Company nor any of its Subsidiaries, directors, officers, or employees, nor, to the
knowledge of the Company, after due inquiry, any agent, affiliate or other person acting on behalf of the Company or any of its Subsidiaries is currently the subject or the target of any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Department of the Treasury (&#8220;<U>OFAC</U>&#8221;) or the U.S. Department of State, the United Nations Security Council, the European Union, His Majesty&#8217;s Treasury of the United Kingdom, or other relevant sanctions
authority (collectively, &#8220;<U>Sanctions</U>&#8221;); nor is the Company or any of its Subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without limitation, Cuba,
Iran, North Korea, Syria, Russia, Venezuela, Kherson, Zaporizhzhia, and the Crimea, <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#8217;s Republic, and <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#8217;s
Republic regions of Ukraine; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any Subsidiary, or any joint venture partner or other person or entity,
for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any other manner that will result in a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the
Company and its Subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any
Sanctioned Country. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxvii) <U>Sarbanes-Oxley</U>. The Company is in compliance, in all material respects, with all
applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxviii)
<U>Cybersecurity</U>. The Company and its Subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#8220;<U>IT Systems</U>&#8221;) are
adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its Subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan
horses, time bombs, malware and other corruptants. The Company and its Subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect
their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including &#8220;Personal Data,&#8221; used in connection with their businesses. &#8220;<U>Personal Data</U>&#8221;
means (i)&nbsp;a natural person&#8217;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#8217;s license number, passport number,
credit card number, bank information, or customer or account number; (ii)&nbsp;any information which would qualify as &#8220;personally identifying information&#8221; under the Federal Trade Commission Act, as amended; (iii) &#8220;personal
data&#8221; as defined by GDPR (defined below); (iv) any information which would qualify as &#8220;protected health information&#8221; under the U.S. Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information
Technology for Economic and Clinical Health Act (collectively, &#8220;<U>HIPAA</U>&#8221;); and (v)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or
analysis of any data related to an identified person&#8217;s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost
or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its Subsidiaries are presently in material compliance with all applicable laws or statutes and all
judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of
such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxix) <U>Compliance
with Data Privacy Laws</U>. The Company and its Subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the
Company and its Subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May&nbsp;25, 2018, have been and currently are in compliance with, the European Union General Data Protection Regulation
(&#8220;<U>GDPR</U>&#8221;) (EU 2016/679) (collectively, the &#8220;<U>Privacy Laws</U>&#8221;). To ensure compliance with the Privacy Laws, the Company and its Subsidiaries have in place, comply with, and take appropriate steps reasonably designed
to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#8220;<U>Policies</U>&#8221;). The
Company and its Subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies
that neither it nor any Subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would
reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order,
decree, or agreement that imposes any obligation or liability under any Privacy Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xl) <U>Accuracy of Exhibits</U>.
There are no contracts or documents which are required to be described in the Registration Statement, the General Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and
filed as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xli) <U>Lending Relationship</U><I>. </I>Except as disclosed in the Registration Statement, the
General Disclosure Package and the Prospectus, the Company (i)&nbsp;does not have any&nbsp;material lending or other relationship with any banking or lending affiliate of any Underwriter and (ii)&nbsp;does not intend to use any of the proceeds from
the sale of the Securities to repay any outstanding debt owed to any affiliate of any Underwriter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xlii) <U>Maintenance
of Rating</U>. The Company has no debt securities or preferred stock that is rated by any &#8220;nationally recognized statistical rating organization&#8221; (as that term is defined by the Commission for purposes of Rule 436(g)(2) under the 1933
Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Officer&#8217;s Certificates</I>. Any certificate signed by any officer of the Company or any of its Subsidiaries delivered
to the Representative or to counsel for the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Sale and Delivery to Underwriters; Closing</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Initial Securities</I>. On the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees to purchase from the Company, at the price per Share and the price per <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, as applicable, set forth in <U>Schedule</U><U></U><U>&nbsp;A</U>, that number of Initial Securities set forth in <U>Schedule</U><U></U><U>&nbsp;A</U> opposite the name of such Underwriter, plus
any additional number of Initial Securities which such Underwriter may become obligated to purchase pursuant to the provisions of Section&nbsp;10 hereof, subject, in each case, to such adjustments among the Underwriters as the Representative in its
sole discretion shall make to eliminate any sales or purchases of fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Option Shares</I>. In addition, on the basis
of the representations and warranties herein contained and subject to the terms and conditions herein set forth, the Company hereby grants an option to the Underwriters, severally and not jointly, to purchase up to an additional 4,545,600 Option
Shares, at the price per share set forth in <U>Schedule</U><U></U><U>&nbsp;A</U>, less an amount per share equal to any dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Shares.
The option hereby granted may be exercised for 30&nbsp;days after the date hereof and may be exercised in whole or in part at any time from time to time upon notice by the Representative to the Company setting forth the number of Option Shares as to
which the several Underwriters are then exercising the option and the time and date of payment and delivery for such Option Shares. Any such time and date of delivery (a &#8220;<U>Date of Delivery</U>&#8221;) shall be determined by the
Representative, but any Date of Delivery after the Closing Time shall not be later than seven full business days nor earlier than two full business days after the exercise of said </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
option, nor in any event prior to the Closing Time. If the option is exercised as to all or any portion of the Option Shares, each of the Underwriters, acting severally and not jointly, will
purchase that proportion of the total number of Option Shares then being purchased which the number of Initial Securities set forth in <U>Schedule A</U> opposite the name of such Underwriter bears to the total number of Initial Securities, subject,
in each case, to such adjustments as the Representative in its sole discretion shall make to eliminate any sales or purchases of fractional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Payment</I>. Payment of the purchase price for, and delivery of certificates or security entitlements for, the Initial Securities shall
be made at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., or at such other place as shall be agreed upon by the Representative and the Company, at 10:00&nbsp;A.M. (New York City time) on the first (second, if the pricing occurs
after 4:30 P.M. (New York City time) on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section&nbsp;10), or such other time not later than ten business days after such date as shall be agreed
upon by the Representative and the Company (such time and date of payment and delivery being herein called &#8220;<U>Closing Time</U>&#8221;). Delivery of the Firm Shares at the Closing Time shall be made through the facilities of The Depository
Trust Company unless the Representative shall otherwise instruct in writing. Notwithstanding the foregoing, the Company and the Representative shall instruct purchasers of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to make
payment for the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants at the Closing Time to the Company by wire transfer in immediately available funds to the account specified by the Company at a purchase price of $1.649 per <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, in lieu of payment by the Underwriters for such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, and the Company shall deliver such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants to such purchasers at the Closing Time in definitive form against such payment, in lieu of the Company&#8217;s obligation to deliver such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to the Underwriters; provided that, the
Representative shall withhold $0.099 per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant with respect to such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants as an offset against the payment owed by the Representative to the
Company with respect to the Securities (with respect to the Option Shares, only to the extent the Underwriters&#8217; option under Section&nbsp;2(b) hereof is exercised concurrently to close at the Closing Time) hereunder. In the event that any
purchaser of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants fails to make payment to the Company for all or part of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants at the Closing Time, the Representative may elect,
by written notice to the Company, to receive shares of Common Stock at the share purchase price specified in <U>Schedule A</U> in lieu of all or a portion of such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to be delivered to the
Underwriters under this Agreement. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants will be made available for inspection by the Representative on the business day prior to the Closing Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event that any or all of the Option Shares are purchased by the Underwriters, payment of the purchase price for, and
delivery of certificates or security entitlements for, such Option Shares shall be made at the <FONT STYLE="white-space:nowrap">above-mentioned</FONT> offices, or at such other place as shall be agreed upon by the Representative and the Company, on
each Date of Delivery as specified in the notice from the Representative to the Company. Delivery of the Option Shares on each such Date of Delivery shall be made through the facilities of The Depository Trust Company unless the Representative shall
otherwise instruct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment shall be made to the Company by wire transfer of immediately available funds to a bank account designated by
the Company, against delivery to the Representative for the respective accounts of the Underwriters of certificates or security entitlements for the Securities to be purchased by them. It is understood that each Underwriter has authorized the
Representative, for its account, to accept delivery of, receipt for, and make payment of the purchase price for, the the Initial Securities and the Option Shares, if any, which it has agreed to purchase. Leerink Partners, individually and not as
representative of the Underwriters, may (but shall not be obligated to) make payment of the purchase price for the Initial Securities and the Option Shares, if any, to be purchased by any Underwriter whose funds have not been received by the Closing
Time or the relevant Date of Delivery, as the case may be, but such payment shall not relieve such Underwriter from its obligations hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Covenants of the Company</U>. The Company covenants with each Underwriter as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Compliance with Securities Regulations and Commission Requests</I>. The Company, subject to Section&nbsp;3(b), will comply
with the requirements of Rule 430B, and, until the later of the Closing Time or the period when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, will
notify the Representative as soon as practicable, and confirm the notice in writing, (i)&nbsp;when any post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been
filed, (ii)&nbsp;of the receipt of any comments from the Commission, (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus (including any document incorporated by
reference therein) or for additional information, (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or suspending the
use of any preliminary prospectus or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any
examination pursuant to Section&nbsp;8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v)&nbsp;if the Company becomes the subject of a proceeding under Section&nbsp;8A of the 1933 Act in connection with the offering of the
Securities. The Company will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain promptly
whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. During the completion of the distribution of the Securities
as contemplated in this Agreement and in the Registration Statement, the Company will use reasonable efforts to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof as soon
as practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Continued Compliance with Securities Laws</I>. The Company will comply with the 1933 Act, the 1933 Act
Regulations, the 1934 Act and the 1934 Act Regulations so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement, the General Disclosure Package and the Prospectus. If at
any time when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (&#8220;<U>Rule 172</U>&#8221;), would be) required by the 1933 Act to be delivered in connection with sales of the
Securities, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i)&nbsp;amend the Registration Statement in order that the Registration Statement
will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii)&nbsp;amend or supplement the General Disclosure Package or the
Prospectus in order that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading
in the light of the circumstances existing at the time it is delivered to a purchaser or (iii)&nbsp;amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply with
the requirements of the 1933 Act or the 1933 Act Regulations, the Company will promptly (A)&nbsp;give the Representative notice of such event, (B)&nbsp;prepare any amendment or supplement as may be necessary to correct such statement or omission or
to make the Registration Statement, the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representative with copies of any such amendment or
supplement and (C)&nbsp;file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representative or counsel for the Underwriters shall reasonably object.
The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company has given the Representative notice of any filings made pursuant to the 1934 Act or the 1934
Act Regulations within 48 hours prior to the Applicable Time; the Company will give the Representative notice of its intention to make any such filing from the Applicable Time to the Closing Time and will furnish the Representative with copies of
any such documents a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representative or counsel for the Underwriters shall reasonably object. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Delivery of Registration Statements</I>. If requested by the Representative, the
Company will furnish or deliver to the Representative and counsel for the Underwriters, without charge, signed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith or incorporated by
reference therein and documents incorporated or deemed incorporated by reference therein) and signed copies of all consents and certificates of experts, and will also deliver to the Representative, without charge, a conformed copy of the
Registration Statement as originally filed and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the
electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Delivery of Prospectuses</I>. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary
prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the 1933 Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus
relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request.
The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Blue Sky Qualifications</I>. The Company will use commercially reasonable efforts, in
cooperation with the Underwriters, to qualify the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representative may reasonable designate and to maintain such
qualifications in effect so long as required to complete the distribution of the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a
dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Rule 158</I>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available
(which may be satisfied by filing such reports with the Commission pursuant to EDGAR) to its securityholders as soon as practicable an earning statement for the purposes of, and to provide to the Underwriters the benefits contemplated by, the last
paragraph of Section&nbsp;11(a) of the 1933 Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Use of Proceeds</I>. The Company will use the net proceeds received by it from
the sale of the Securities in all material respects in the manner specified in the Registration Statement, the General Disclosure Package and the Prospectus under the heading &#8220;Use of Proceeds.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Listing</I>. The Company will use commercially reasonable efforts to effect and maintain the listing of the Common Stock (including the
Shares and Warrant Shares) on the Nasdaq Capital Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Warrant Shares Reserved</I>. The Company shall, at all times while any <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved shares of Common Stock, solely for the purpose of enabling it to issue
Warrant Shares upon exercise of such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of the then-outstanding
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Restriction on Sale of Securities</I>. During a period of 60 days
from the date of the Prospectus, the Company will not, without the prior written consent of the Representative, (i)&nbsp;directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file or confidentially submit any
registration statement under the 1933 Act with respect to any of the foregoing, (ii)&nbsp;enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of
ownership of the Common Stock, whether any such swap or transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (iii)&nbsp;publicly announce an intention
to effect any such swap, agreement or other transaction described in clauses (i)&nbsp;and (ii). The foregoing sentence shall not apply to (A)&nbsp;the Securities to be sold hereunder; (B)&nbsp;any shares of Common Stock issued by the Company upon
the exercise (including any net exercise or exercise by delivery of already owned shares of Common Stock) of an option or warrant or upon vesting of restricted stock units or the conversion of a convertible security outstanding on the date hereof
and referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (C)&nbsp;any shares of Common Stock issued or options to purchase Common Stock granted pursuant to existing employee benefit or equity incentive plans
of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (D)&nbsp;any shares of Common Stock issued or options to purchase shares of, or restricted stock units with respect to, Common Stock granted
pursuant to any existing <FONT STYLE="white-space:nowrap">non-employee</FONT> director stock plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus; or (E)&nbsp;the filing by
the Company of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)
<I>Reporting Requirements</I>. The Company, during the period when a Prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to
be filed with the Commission pursuant to the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations. Additionally, the Company shall report the use of proceeds from the issuance of the Securities as may be required under
Rule 463 under the 1933 Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Issuer Free Writing Prospectuses</I>. The Company agrees that, unless it obtains the prior written
consent of the Representative, it will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#8220;free writing prospectus,&#8221; or a portion thereof, required
to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the Representative will be deemed to have consented to the Issuer Free Writing Prospectuses listed on <U>Schedule</U><U></U><U><FONT
STYLE="white-space:nowrap">&nbsp;B-2</FONT></U> hereto and any &#8220;road show that is a written communication&#8221; within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representative. The Company represents that it has treated
or agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Representative as an &#8220;issuer free writing prospectus,&#8221; as defined in Rule 433, and that it has complied and will comply with the
applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an
event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus or included or would include an
untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly
notify the Representative and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Payment of Expenses</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Expenses</I>. The Company will pay or cause to be paid all expenses incident to the performance of its obligations under this
Agreement, including (i)&nbsp;the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and each amendment thereto, (ii)&nbsp;the preparation, printing and delivery to the
Underwriters of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Underwriters to
investors, (iii)&nbsp;the preparation, issuance and delivery of the certificates or security entitlements for the Securities to the Underwriters, including any stock or other transfer taxes and any stamp or other duties payable upon the sale,
issuance or delivery of the Securities to the Underwriters, (iv)&nbsp;the fees and disbursements of the Company&#8217;s counsel, accountants and other advisors, (v)&nbsp;the qualification of the Securities under securities laws in accordance with
the provisions of Section&nbsp;3(e) hereof, including filing fees and the reasonable and documented fees and disbursements of counsel for the Underwriters in connection therewith and in connection with the preparation of a &#8220;Blue Sky
Survey&#8221; and any supplement thereto (which fees and disbursements of counsel, together with the fees from subclause (viii), shall not exceed $10,000), (vi) the fees and expenses of any transfer agent or registrar for the Securities,
(vii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#8220;road show&#8221; undertaken in connection with the marketing of the Securities, including without limitation, expenses associated with the production
of road show slides and graphics, fees and expenses of any consultants engaged with the Company&#8217;s consent in connection with the road show presentations, travel and lodging expenses of the representatives and officers of the Company and any
such consultants (provided that the lodging and any car travel expenses of the Underwriters shall be paid by the Underwriters), and 50% of the cost of aircraft and other transportation chartered in connection with the road show, (viii)&nbsp;the
filing fees incident to, and the reasonable fees and disbursements of counsel to the Underwriters in connection with, the review by FINRA of the terms of the sale of the Securities (which fees and disbursements of counsel, together with the fees
from subclause (v), shall not exceed $10,000), (xi) the fees and expenses incurred in connection with the listing of the Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares on the Nasdaq Capital Market, and (x)&nbsp;the
costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the Securities made by the Underwriters caused by a
breach of the representation contained in the third sentence of Section&nbsp;1(a)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Termination of Agreement</I>. If this
Agreement is terminated by the Representative in accordance with the provisions of Section&nbsp;5, Section&nbsp;9(a)(i), Section&nbsp;9(a)(iii) or Section&nbsp;10 hereof, the Company shall reimburse the Underwriters; provided, however, that if this
Agreement is terminated pursuant to Section&nbsp;10, the Company shall have no obligation to reimburse any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by any defaulting Underwriter.
for all of their reasonably documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, including the reasonable and documented fees and disbursements of counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Conditions of Underwriters&#8217; Obligations</U>. The obligations of the several Underwriters hereunder are subject to the
accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or any of its Subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its
covenants and other obligations hereunder, and to the following further conditions: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Effectiveness of Registration Statement</I>. The Registration Statement, including
any Rule 462(b) Registration Statement, has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order
preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&#8217;s knowledge, contemplated by the Commission;
and the Company has complied with each request (if any) from the Commission for additional information to the reasonable satisfaction of counsel to the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Opinion of Counsel for Company</I>. At the Closing Time, the Representative shall have received the opinion and the negative assurance
letter, each dated the Closing Time, of O&#8217;Melveny&nbsp;&amp; Myers LLP, counsel for the Company, together with the opinion of Sterne, Kessler, Goldstein&nbsp;&amp; Fox PLLC, special counsel for the Company with respect to intellectual property
matters, each in form and substance satisfactory to counsel for the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Opinion of Counsel for Underwriters</I>. At the
Closing Time, the Representative shall have received the opinion, and negative assurance letter, each dated the Closing Time, of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the Underwriters, together with signed or reproduced
copies of such letters for each of the other Underwriters in form and substance satisfactory to the Representative. In giving such opinion such counsel may rely, as to all matters governed by the laws of jurisdictions other than the law of the State
of New York, the General Corporation Law of the State of Delaware and the federal securities laws of the United States, upon the opinions of counsel satisfactory to the Representative. Such counsel may also state that, insofar as such opinion
involves factual matters, they have relied, to the extent they deem proper, upon certificates of officers and other representatives of the Company and its Subsidiaries and certificates of public officials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Officers&#8217; Certificate</I>. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as
of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the
Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, and the Representative shall have received a certificate of the principal executive officer of the Company and of the principal
financial officer of the Company, dated the Closing Time, to the effect that (i)&nbsp;there has been no such material adverse change, (ii)&nbsp;the representations and warranties of the Company in this Agreement are true and correct with the same
force and effect as though expressly made at and as of the Closing Time, (iii)&nbsp;the Company has complied in all material respects with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior to the
Closing Time, and (iv)&nbsp;no stop order suspending the effectiveness of the Registration Statement under the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no
proceedings for any of those purposes have been instituted or are pending or, to their knowledge, contemplated by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
<I>Accountant&#8217;s Comfort Letter</I>. At the time of the execution of this Agreement, the Representative shall have received from each of Deloitte&nbsp;&amp; Touche LLP, Crowe LLP and KMJ Corbin&nbsp;&amp; Company LLP a letter, dated such date,
in form and substance satisfactory to the Representative, together with signed or reproduced copies of such letters for each of the other Underwriters containing statements and information of the type ordinarily included in accountants&#8217;
&#8220;comfort letters&#8221; to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the General Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Bring-down Comfort Letter</I>. At the Closing Time, the Representative shall have received from each of Deloitte&nbsp;&amp; Touche LLP,
Crowe LLP and KMJ Corbin&nbsp;&amp; Company LLP a letter, dated as of the Closing Time, to the effect that they reaffirm the statements made in the letters furnished pursuant to subsection (e)&nbsp;of this Section, except that the specified date
referred to shall be a date not more than two business days prior to the Closing Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Approval of Listing</I>. At the Closing Time, the Company shall have made all
required submissions to the Nasdaq Capital Market regarding the Securities and shall have not received any notice objecting to the listing of the Shares and the Warrant Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>No Objection</I>. FINRA has confirmed that it has not raised any objection with respect to the fairness and reasonableness of the
underwriting terms and arrangements relating to the offering of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I><FONT STYLE="white-space:nowrap">Lock-up</FONT>
Agreements</I>. At the date of this Agreement, the Representative shall have received an agreement substantially in the form of <U>Exhibit</U><U></U><U>&nbsp;A</U> hereto signed by all of the Company&#8217;s directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Chief Financial Officer&#8217;s Certificate.</I> On the date of this Agreement and at the Closing Time, the Representative shall have
received from the Company a certificate of its principal financial officer with respect to certain financial data contained in the General Disclosure Package and the Prospectus, which certificate shall be in form and substance satisfactory to
counsel for the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Maintenance of Rating</I>. Neither the Company nor its Subsidiaries have any debt securities or
preferred stock that are rated by any &#8220;nationally recognized statistical rating agency&#8221; (as defined in Section&nbsp;3(a)(62) of the 1934 Act). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Conditions to Purchase of Option Shares</I>. In the event that the Underwriters exercise their option provided in Section&nbsp;2(b)
hereof to purchase all or any portion of the Option Shares, the representations and warranties of the Company contained herein and the statements in any certificates furnished by the Company hereunder shall be true and correct as of each Date of
Delivery and, at the relevant Date of Delivery, the Representative shall have received: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Officers&#8217;
Certificate</U>. A certificate, dated such Date of Delivery, of the principal executive officer of the Company and of the principal financial officer of the Company confirming that the certificate delivered at the Closing Time pursuant to
Section&nbsp;5(d) hereof remains true and correct as of such Date of Delivery. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Opinion of Counsel for Company</U>.
If requested by the Representative, the opinion and negative assurance letter of O&#8217;Melveny&nbsp;&amp; Myers LLP, counsel for the Company, together with the opinion of Sterne, Kessler, Goldstein&nbsp;&amp; Fox PLLC, special counsel for the
Company with respect to intellectual property matters, each in form and substance satisfactory to counsel for the Underwriters, dated such Date of Delivery, relating to the Option Shares to be purchased on such Date of Delivery and otherwise to the
same effect as the opinions and negative assurance letter required by Section&nbsp;5(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Opinion of
Counsel for Underwriters</U>. If requested by the Representative, the opinion and negative assurance letter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the Underwriters, dated such Date of Delivery, relating to the Option
Shares to be purchased on such Date of Delivery and otherwise to the same effect as the opinion and negative assurance letter required by Section&nbsp;5(c) hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>Bring-down Comfort Letter</U>. If requested by the Representative, a
letter from each of Deloitte&nbsp;&amp; Touche LLP, Crowe LLP and KMJ Corbin&nbsp;&amp; Company LLP, in form and substance satisfactory to the Representative and dated such Date of Delivery, substantially in the same forms and substance as the
letters furnished to the Representative pursuant to subsection (f)&nbsp;of this Section, except that the &#8220;specified date&#8221; in the letter furnished pursuant to this paragraph shall be a date not more than two business days prior to such
Date of Delivery. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Chief Financial Officer&#8217;s Certificate</U>. A certificate, dated such Date of Delivery, of
the principal financial officer of the Company confirming that the certificate delivered at the Closing Time pursuant to Section&nbsp;5(j) hereof remains true and correct as of such Date of Delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Additional Documents</I>. At the Closing Time and at each Date of Delivery (if any), counsel for the Underwriters shall have been
furnished with such other documents and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the
representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated shall be reasonably satisfactory
in form and substance to the Representative and counsel for the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Termination of Agreement</I>. If any condition
specified in this Section shall not have been fulfilled when and as required to be fulfilled, this Agreement, or, in the case of any condition to the purchase of Option Shares on a Date of Delivery which is after the Closing Time, the obligations of
the several Underwriters to purchase the relevant Option Shares, may be terminated by the Representative by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the case may be, and such termination shall be
without liability of any party to any other party except as provided in Section&nbsp;4 and except that Sections 1, 4, 6, 7, 8, 14, 15 and 16 shall survive any such termination and remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Indemnification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of Underwriters</I>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as such term
is defined in Rule 501(b) under the 1933 Act (each, an &#8220;<U>Affiliate</U>&#8221;)), its selling agents and each person, if any, who controls any Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934
Act as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) against any and all loss, liability, claim, damage and reasonably incurred expense whatsoever, as
incurred, arising out of any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, or the
omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material fact included
(A)&nbsp;in any preliminary prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto), or (B)&nbsp;in any materials or information provided to investors by, or with the
approval of, the Company in connection with the marketing of the offering of the Securities (&#8220;<U>Marketing Materials</U>&#8221;), including any roadshow or investor presentations made to investors by the Company (whether in person or
electronically), or the omission or alleged omission in any preliminary prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus (or any amendment or supplement thereto) or in any Marketing Materials of a
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) against any and all loss, liability, claim, damage and reasonably
incurred expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based
upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to Section&nbsp;6(d) below) any such settlement is effected with the written consent of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) against any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the
Representative), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue
statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under (i)&nbsp;or (ii) above; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue
statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the
Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<I>Indemnification of Company, Directors and Officers</I>. Each Underwriter severally agrees to indemnify and hold harmless the Company, its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls
the Company within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act, against any and all loss, liability, claim, damage and reasonably incurred expense described in the indemnity contained in subsection (a)&nbsp;of
this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof
pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Actions against Parties; Notification</I>. Each indemnified party shall give notice as promptly as reasonably practicable to each
indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent it is
not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. In the case of parties indemnified pursuant to Section&nbsp;6(a) above,
counsel to the indemnified parties shall be selected by the Representative, and, in the case of parties indemnified pursuant to Section&nbsp;6(b) above, counsel to the indemnified parties shall be selected by the Company. An indemnifying party may
participate at its own expense in the defense of any such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. In no event shall the
indemnifying parties be liable for the reasonable and documented fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate
but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the
entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under
this Section&nbsp;6 or Section&nbsp;7 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i)&nbsp;includes an unconditional release of each indemnified party from
all liability arising out of such litigation, investigation, proceeding or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Settlement without Consent if Failure to Reimburse</I>. If at any time an indemnified
party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section&nbsp;6(a)(ii)
effected without its written consent if (i)&nbsp;such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party shall have received notice of the terms of such
settlement at least 30 days prior to such settlement being entered into and (iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Contribution</U>. If the indemnification provided for in Section&nbsp;6 hereof is for any reason unavailable to or insufficient
to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and
expenses incurred by such indemnified party, as incurred, (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the
Securities pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above
but also the relative fault of the Company, on the one hand, and of the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other
relevant equitable considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The relative benefits received by the Company, on the one hand, and the Underwriters, on the other
hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this Agreement (before deducting
expenses) received by the Company, on the one hand, and the total underwriting discount received by the Underwriters, on the other hand, in each case as set forth on the cover of the Prospectus, bear to the aggregate public offering price of the
Securities as set forth on the cover of the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The relative fault of the Company, on the one hand, and the Underwriters, on the
other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or by
the Underwriters and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;7 were determined
by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this Section&nbsp;7. The aggregate
amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section&nbsp;7 shall be deemed to include any documented legal or other expenses reasonably incurred by such indemnified party
in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or
omission or alleged omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this Section&nbsp;7, no Underwriter shall be required to contribute any
amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Securities underwritten by it and distributed to the public. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)
of the 1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes
of this Section&nbsp;7, each person, if any, who controls an Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act and each Underwriter&#8217;s Affiliates and selling agents shall have the same rights
to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the 1933 Act or
Section&nbsp;20 of the 1934 Act shall have the same rights to contribution as the Company. The Underwriters&#8217; respective obligations to contribute pursuant to this Section&nbsp;7 are several in proportion to the number of Initial Securities set
forth opposite their respective names in <U>Schedule</U><U></U><U>&nbsp;A</U> hereto and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Representations,
Warranties and Agreements to Survive</U>. All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company or any of its Subsidiaries submitted pursuant hereto, shall remain operative and in
full force and effect regardless of (i)&nbsp;any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company and
(ii)&nbsp;delivery of and payment for the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Termination of Agreement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Termination</I>. The Representative may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing Time
(i)&nbsp;if there has been, in the judgment of the Representative, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the
Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary
course of business, or (ii)&nbsp;if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any material adverse outbreak of hostilities or escalation thereof or other
calamity or crisis or any change or development involving a prospective change in U.S. or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representative,
impracticable or inadvisable to proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii)&nbsp;if trading in any securities of the Company has been suspended or materially limited by the Commission
or the Nasdaq Capital Market, or (iv)&nbsp;if trading generally on the NYSE MKT or the New York Stock Exchange or in the Nasdaq Capital Market has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or
maximum ranges for prices have been required, by any of said exchanges or by order of the Commission, FINRA or any other governmental authority, or (v)&nbsp;a material disruption has occurred in commercial banking or securities settlement or
clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe, or (vi)&nbsp;if a banking moratorium has been declared by either Federal or New York authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Liabilities</I>. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to
any other party except as provided in Section&nbsp;4 hereof, and provided further that Sections 1, 4, 6, 7, 8, 14, 15, 16 and 17 shall survive such termination and remain in full force and effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Default by One or More of the Underwriters</U>. If one or more of the
Underwriters shall fail at the Closing Time or a Date of Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the &#8220;<U>Defaulted Securities</U>&#8221;), the Representative shall have the right,
within 24&nbsp;hours thereafter, to make arrangements for one or more of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such
amounts as may be agreed upon and upon the terms herein set forth; if, however, the Representative shall not have completed such arrangements within such <FONT STYLE="white-space:nowrap">24-hour</FONT> period, then: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) if the number of Defaulted Securities does not exceed 10% of the number of Securities to be purchased on such date, each of
the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective underwriting obligations hereunder bear to the
underwriting obligations of all <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if the number
of Defaulted Securities exceeds 10% of the number of Securities to be purchased on such date, this Agreement or, with respect to any Date of Delivery which occurs after the Closing Time, the obligation of the Underwriters to purchase, and the
Company to sell, the Option Shares to be purchased and sold on such Date of Delivery shall terminate without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No action taken pursuant to this Section shall relieve any defaulting Underwriter from liability in respect of its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any such default which does not result in a termination of this Agreement or, in the case of a Date of Delivery which is after
the Closing Time, which does not result in a termination of the obligation of the Underwriters to purchase and the Company to sell the relevant Option Shares, as the case may be, either the (i)&nbsp;Representative or (ii)&nbsp;the Company shall have
the right to postpone Closing Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the Registration Statement, the General Disclosure Package or the Prospectus or
in any other documents or arrangements. As used herein, the term &#8220;Underwriter&#8221; includes any person substituted for an Underwriter under this Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if
mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to Leerink Partners at 1301 Avenue of the Americas, 5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, New York, New York,
10019, attention of Stuart R. Nayman. Notices to the Company shall be directed to Eledon Pharmaceuticals, Inc., 19800 MacArthur Blvd., Suite 250, Irvine, CA 92612, Attn: Bryan Smith, with a copy to O&#8217;Melveny&nbsp;&amp; Myers LLP, 610 Newport
Center Drive, 17<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, Newport Beach, California 92660, Attn: Shelly Heyduk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12. <U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a)&nbsp;the purchase and sale of the
Securities pursuant to this Agreement, including the determination of the initial public offering price of the Securities and any related discounts and commissions, is an <FONT STYLE="white-space:nowrap">arm&#8217;s-length</FONT> commercial
transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering of the Securities and the process leading thereto, each Underwriter is and has been acting solely as a
principal and is not the agent or fiduciary of the Company, any of its Subsidiaries or their respective stockholders, creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will assume an advisory or fiduciary responsibility
in favor of the Company with respect to the offering of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company or any of its Subsidiaries on other matters) and no
Underwriter has any obligation to the Company with respect to the offering of the Securities except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be engaged in a broad range of
transactions that involve interests that differ from those of the Company and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering of the Securities and the Company has consulted
its own respective legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>Recognition of the U.S. Special Resolution Regimes</U>. In the event that any
Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the
same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a
U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution
Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement,
(A) &#8220;BHC Act Affiliate&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#8220;Covered Entity&#8221; means any of the following: (i)&nbsp;a
&#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or
(iii)&nbsp;a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b); (C) &#8220;Default Right&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with,
12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (D) &#8220;U.S. Special Resolution Regime&#8221; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the
Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>Parties</U>. This
Agreement shall each inure to the benefit of and be binding upon the Underwriters and the Company and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or
corporation, other than the Underwriters and the Company and their respective successors and the controlling persons and officers and directors referred to in Sections&nbsp;6 and 7 and their heirs and legal representatives, any legal or equitable
right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters and the Company and
their respective successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be
deemed to be a successor by reason merely of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>Waiver of Trial by Jury</U>. The Company (on its behalf and,
to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal
proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 16. <U>GOVERNING LAW</U>. THIS
AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 17. <U>Consent to Jurisdiction; Waiver of Immunity</U>. Any legal suit, action or
proceeding arising out of or based upon this Agreement or the transactions contemplated hereby shall&nbsp;be instituted in (i) the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan
or&nbsp;(ii) the courts of the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the &#8220;<U>Specified Courts</U>&#8221;), and each party irrevocably submits to the exclusive jurisdiction (except for
proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any
process, summons, notice or document by mail to such party&#8217;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive
any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought
in any such court has been brought in an inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 18. <U>TIME</U>. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT.
EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 19. <U>Partial Unenforceability</U>.
The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement
is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 20. <U>Counterparts</U>. This Agreement may be executed in any number of counterparts (which may include counterparts delivered by any
standard form of telecommunication), each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any
electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so
delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 21. <U>Effect of
Headings</U>. The Section headings herein are for convenience only and shall not affect the construction hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 22. <U>Entire
Agreement</U>. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGES FOLLOW] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Very truly yours,</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ELEDON PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ David-Alexandre C. Gros, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: David-Alexandre C. Gros, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">CONFIRMED AND ACCEPTED</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">&#8195;As of the date first above written:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LEERINK PARTNERS LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Dan Dubin, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Dan Dubin, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Global Co-Head of Investment Banking</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For itself and as Representative of the other Underwriters named in <U>Schedule</U><U></U><U>&nbsp;A</U> hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> U<SMALL>NDERWRITING</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The public offering price per Share shall be $1.65 and the public offering price per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant shall be
$1.649. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per Share to be paid by the several Underwriters shall be $1.551, being an amount equal to the public offering price set forth
above less $0.099 per Share, and shall be $1.55 per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, being an amount equal to the public offering price set forth above less $0.099 per share underlying the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, in each case, subject to adjustment in accordance with Section&nbsp;2(b) for dividends or distributions declared by the Company and payable on the Securities but not payable on the Option
Shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Name of Underwriter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>Firm&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">Number&nbsp;of&nbsp;Pre-Funded&nbsp;Warrants</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,091,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,090,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,545,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,545,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LifeSci Capital LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,515,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,515,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>15,152,485</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>15,151,515</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE <FONT STYLE="white-space:nowrap">B-1</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Terms </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The Company is selling
15,152,485 Firm Shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. The Company is selling <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to purchase up to
15,151,515 shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. The public offering price per Share shall be $1.65 and the public offering price per
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant shall be $1.649. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The Company has granted an option to the Underwriters, severally and not
jointly, to purchase up to 4,545,600 Option Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE <FONT STYLE="white-space:nowrap">B-2</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Free Writing Prospectuses </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">November &#8195;, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Representative of the several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o&#8195;&#8195;Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53 State Street, 40<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02109 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Proposed Offering by Eledon Pharmaceuticals, Inc.</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, an
officer and/or director of Eledon Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<U>Company</U>&#8221;), understands that Leerink Partners LLC (&#8220;<U>Leerink Partners</U>&#8221;) proposes to enter into an Underwriting Agreement (the
&#8220;<U>Underwriting Agreement</U>&#8221;) with the Company providing for the offering (the &#8220;<U>Offering</U>&#8221;) of shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<U>Common Stock</U>&#8221;) and/or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase Common Stock. In recognition of the benefit that such an offering will confer upon the undersigned as an officer and/or a director of the Company, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the Underwriting Agreement (collectively, the &#8220;<U>Underwriters</U>&#8221;) that, during the period
beginning on the date hereof and ending on the date that is 60 days from the date of the Underwriting Agreement (the &#8220;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</U>&#8221;), the undersigned will not, without the prior written
consent of Leerink Partners, on behalf of the Underwriters, directly or indirectly, (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant
for the sale of, or otherwise dispose of or transfer any shares of Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which
the undersigned has or hereafter acquires the power of disposition (collectively, the &#8220;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities</U>&#8221;), or exercise any right with respect to the registration of any of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act of 1933, as amended, or (ii)&nbsp;enter into any swap or any other agreement or any
transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such swap or transaction is to be settled by delivery of
Common Stock or other securities, in cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, and subject to the conditions below, the
undersigned may transfer <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities without the prior written consent of Leerink Partners, provided, in each case, that (1)&nbsp;in the cases of clauses (i)-(v) below, Leerink Partners receives a
signed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement for the balance of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period from each donee, trustee, distributee, or transferee, as the case may be, (2)&nbsp;any such transfer shall
not involve a disposition for value, (3)&nbsp;if the undersigned is required to file a report under Section&nbsp;16 of the Securities Exchange Act of 1934, as amended (the &#8220;<U>Exchange Act</U>&#8221;), in connection with such transfer during
the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, the undersigned shall (A)&nbsp;in the case of any transfer pursuant to clause (i), (ii), (iii) or (v)&nbsp;below, file such report using transaction code &#8220;G&#8221; and include a
statement in such report to the effect that such transfer is being made as a gift or by will or intestate succession, as applicable, and (B)&nbsp;in the case of any withholding or repurchase of <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Securities by the Company pursuant to clause (vi)&nbsp;below in connection with the vesting or exercise of any option, stock unit or restricted stock </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
award, file such report using transaction code &#8220;F&#8221; and include a statement in such report to the effect that such transfer is being made to satisfy tax withholding obligations, and
(4)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers (other than a filing on a Form 5 made after the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a <I>bona fide</I> gift or gifts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned
(for purposes of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the undersigned&#8217;s affiliates or to any investment fund or other entity controlled or managed by the
undersigned; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to a qualified domestic relations order or in connection with a divorce settlement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by will or intestate succession upon the death of the undersigned; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the Company in satisfaction of any tax withholding obligation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, no provision in this letter shall be deemed to restrict or prohibit (1)&nbsp;the transfer of the undersigned&#8217;s <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities to the Company in connection with the termination of the undersigned&#8217;s services to the Company, provided that any filing under Section&nbsp;16 of the Exchange Act made in connection with
such transfer shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause (1); (2) the exercise or exchange by the undersigned of any option or warrant to acquire any shares of Common Stock
or options to purchase shares of Common Stock, in each case for cash or on a &#8220;cashless&#8221; or &#8220;net exercise&#8221; basis, pursuant to any stock option, stock bonus or other stock plan or arrangement; provided, however, that the
underlying shares of Common Stock shall continue to be subject to the restrictions on transfer set forth in this letter and that any filing under Section&nbsp;16 of the Exchange Act made in connection with such exercise or exchange shall clearly
indicate in the footnotes thereto that (a)&nbsp;the filing relates to the circumstances described in this clause (2)&nbsp;and (b) no shares were sold by the reporting person; (3)&nbsp;the transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Securities upon the completion of a bona fide third-party tender offer, merger, consolidation or other similar transaction made to all holders of the Company&#8217;s securities involving a change of control of the Company; provided, however, that in
the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the undersigned shall remain subject to the restrictions on transfer set forth in this letter; and (4)&nbsp;the conversion of
outstanding preferred stock of the Company into shares of Common Stock, provided that any such shares received upon such conversion shall be subject to the restrictions on transfer set forth in this letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, nothing herein shall prevent the undersigned from establishing a <FONT
STYLE="white-space:nowrap">10b5-1</FONT> trading plan that complies with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act (&#8220;<U><FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan</U>&#8221;) or from amending
an existing <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan so long as there are no sales of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities under any such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; provided, however, that any public announcement or filing under the Exchange Act regarding the establishment or amendment of such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan
shall clearly disclose that no shares of Common Stock shall be disposed by such plan during the duration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#8217;s transfer agent and registrar
against the transfer of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities except in compliance with the foregoing restrictions. This <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement shall automatically terminate, and the
undersigned shall be released from the undersigned&#8217;s obligations hereunder, upon the earliest to occur, if any, of (i)&nbsp;prior </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the execution of the Underwriting Agreement, the Company advises Leerink Partners in writing that it has determined not to proceed with the Offering; (ii)&nbsp;the Underwriting Agreement is
executed but is terminated prior to the closing of the Offering (other than the provisions thereof which survive termination), or (iii)&nbsp;November&nbsp;30, 2025, in the event that the Underwriting Agreement has not been executed by such date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement shall be governed by, and construed in accordance with, the laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS]
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Officer or Director <I>(Print exact name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> L<SMALL>OCK</SMALL><FONT STYLE="white-space:nowrap">-U</FONT><SMALL>P</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELEDON PHARMACEUTICALS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant
Shares: _______ Issue Date:______, 20__ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initial Exercise Date: _______, 20__ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE COMMON STOCK (the &#8220;<U>Warrant</U>&#8221;) certifies that,
for value received, _____________ or its assigns (the &#8220;<U>Holder</U>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the
&#8220;<U>Initial Exercise Date</U>&#8221;) and until this Warrant is exercised in full (the &#8220;<U>Termination Date</U>&#8221;) but not thereafter, to subscribe for and purchase from Eledon Pharmaceuticals, Inc., a Delaware corporation (the
&#8220;<U>Company</U>&#8221;), up to ______ shares (as subject to adjustment hereunder, the &#8220;<U>Warrant Shares</U>&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<U>Common Stock</U>&#8221;). The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;3(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;1.</U> <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set
forth in that certain Underwriting Agreement (the &#8220;<U>Underwriting Agreement</U>&#8221;), dated November&nbsp;12, 2025, among the Company and Leerink Partners LLC, as representative of the underwriters named in Schedule A thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;2.</U> <U>Issuance of Securities; Registration of Warrants</U>. The Warrant, as initially issued by the Company,
is offered and sold pursuant to the Registration Statement. As of the Initial Exercise Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or
an exchange meeting the requirements of Section&nbsp;3(a)(9) of the 1934 Act as in effect on the Initial Exercise Date, the Warrant Shares, are not &#8220;restricted securities&#8221; under Rule 144 promulgated under the 1933 Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;3.</U> <U>Exercise</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or
times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by <FONT STYLE="white-space:nowrap">e-mail</FONT> (or
<FONT STYLE="white-space:nowrap">e-mail</FONT> attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<U>Notice of Exercise</U>&#8221;). Within five (5)&nbsp;Trading Days following the date of exercise as aforesaid, the Holder
shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in
Section&nbsp;3(c) below is specified in the applicable Notice of Exercise. No <FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder
and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading Days of the date on which the final Notice of Exercise is delivered to the Company.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to
the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1)&nbsp;Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Exercise Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was <FONT
STYLE="white-space:nowrap">pre-funded</FONT> to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.001 per Warrant Share) shall be required to be paid by
the Holder to any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind
(&#8220;<U>Person</U>&#8221;) to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such <FONT STYLE="white-space:nowrap">pre-paid</FONT> aggregate exercise price under any
circumstance or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.001, subject to adjustment hereunder (the &#8220;<U>Exercise Price</U>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Cashless Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless
exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing <FONT STYLE="white-space:nowrap">[(A-B)</FONT> (X)] by (A), where: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of
Exercise if such Notice of Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;3(a) hereof on a day that is not a Trading Day or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(2) both executed and delivered pursuant to Section&nbsp;3(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b)(68) of Regulation NMS
promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the option of the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z)&nbsp;the Bid Price of
the Common Stock on the Principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a
Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section&nbsp;3(a) hereof or (iii)&nbsp;the VWAP on the date of
the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section&nbsp;3(a) hereof after the close of &#8220;regular trading hours&#8221; on such
Trading Day; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exercise Price of this Warrant, as adjusted hereunder; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(X)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms
of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Bid
Price</U>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or
the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX
is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and
if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all
other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Principal Trading Market</U>&#8221; means the Trading Market on which
the Common Stock is primarily listed on and quoted for trading, which as of the initial issuance date of this Warrant is the Nasdaq Capital Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Trading Days</U>&#8221; means any weekday on which the Principal Trading Market is normally open for trading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Trading Market</U>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading
on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>VWAP</U>&#8221; means, for any date, the price determined by the first of the
following clauses that applies: (a)&nbsp;if the Common Stock is then listed or quoted on the Nasdaq Capital Market or any other national securities exchange, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Nasdaq Capital Market or other national securities exchange, as applicable, on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02
p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock is then reported in The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of
the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Warrant Shares are issued in
such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9) of the 1933 Act and Rule 144 promulgated under the 1933 Act, the Warrant Shares shall be deemed to have been acquired by the Holder, take on the
characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. In the event that the Registration Statement registering the issuance of Warrant
Shares is, for any reason, not effective at the time of exercise of this Warrant, then the Warrant may only be exercised through a cashless exercise, as set forth in this Section&nbsp;3(c). Except as set forth in Section&nbsp;3(d)(iv) and
Section&nbsp;3(d)(iv), in no event will the exercise of this Warrant be settled in cash. The Company agrees not to take any position contrary to this Section&nbsp;3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Mechanics of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Delivery of Warrant Shares Upon Exercise</U>. Following delivery of the Notice of Exercise, the Company shall cause the
Warrant Shares purchased hereunder to be transmitted by the Company&#8217;s transfer agent (the &#8220;<U>Transfer Agent</U>&#8221;) to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The
Depository Trust Company (&#8220;<U>DTC</U>&#8221;) through its Deposit or Withdrawal at Custodian system (&#8220;<U>DWAC</U>&#8221;) if the Company is then a participant in such system and either (A)&nbsp;there is an effective registration
statement permitting the issuance of the Warrant Shares to the Holder or the resale of the Warrant Shares by the Holder or (B)&nbsp;the Warrant Shares are eligible for resale by the Holder without volume or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name
of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the latest of (i)&nbsp;one (1) Trading Day
after the delivery to the Company of the Notice of Exercise and (ii)&nbsp;one (1) Trading Day after delivery of the aggregate Exercise Price and Notice of Exercise to the Company (such date, the &#8220;<U>Warrant Share Delivery Date</U>&#8221;). If
(A)&nbsp;and (B) above are not true, the Transfer Agent will either (i)&nbsp;record the Warrant Shares in the name of the Holder or its designee on the certificates reflecting the Warrant Shares with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
an appropriate legend regarding restriction on transferability, which shall be issued and dispatched by overnight courier to the address as specified in the Notice of Exercise, and on the
Company&#8217;s share register or (ii)&nbsp;issue such Warrant Shares in the name of the Holder or its designee in restricted book-entry form in the Company&#8217;s share register. Upon delivery of the Notice of Exercise, the Holder shall be deemed
for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the third Trading Day following
the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the
applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the eighth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are
delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the DTC Fast Automated Securities Transfer Program program so long as this Warrant remains outstanding and exercisable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the
request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this
Warrant, which new Warrant shall in all other respects be identical with this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iii. <U>Rescission Rights</U>. If
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;3(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iv. <U>Compensation for <FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver Warrant Shares Upon
Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;3(d)(i) above pursuant to an
exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<U><FONT STYLE="white-space:nowrap">Buy-In</FONT></U>&#8221;), then the Company shall (A)&nbsp;pay in
cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the
number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the
option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such
purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in
respect of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or
in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">v. <U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be
issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction
in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any
transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for <FONT STYLE="white-space:nowrap">same-day</FONT> processing of any Notice of Exercise and all fees to the DTC (or another established clearing corporation
performing similar functions) required for <FONT STYLE="white-space:nowrap">same-day</FONT> electronic delivery of the Warrant Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vii. <U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the
timely exercise of this Warrant, pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Holder&#8217;s Exercise Limitations</U>. The Company shall not
effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section&nbsp;3 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the
applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates (as such term is defined in Rule 405 under the 1933 Act), and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates
(such Persons, &#8220;<U>Attribution Parties</U>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by
the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common
Stock which would be issuable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock,
including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitled the holder thereof to receive Common stock
(&#8220;<U>Common Stock Equivalents</U>&#8221;)) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in
the preceding sentence, for purposes of this Section&nbsp;3(e), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the 1934 Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder
that the Company is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d) of the 1934 Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that
the limitation contained in this Section&nbsp;3(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of
this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm
the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d) of the 1934 Act and the rules and regulations promulgated thereunder. For
purposes of this Section&nbsp;3(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the Company&#8217;s most recent periodic or annual
report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock
outstanding. Upon the written or oral request of a Holder, the Company shall within one (1)&nbsp;Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of
outstanding shares of Common Stock was reported. The &#8220;<U>Beneficial Ownership Limitation</U>&#8221; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of
Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;3(e), provided that to the extent required under Nasdaq
Marketplace Rules, the Beneficial Ownership Limitation in no event exceeds 19.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by
the Holder and the provisions of this Section&nbsp;3(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;3(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4.</U> <U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued
by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number
of shares, or (iv)&nbsp;issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares
of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon
exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;4(a) shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re classification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;4(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all of the record holders of any class of shares of Common Stock (the &#8220;<U>Purchase Rights</U>&#8221;), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this
Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if
no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (such date, the &#8220;<U>Rights Determination Date</U>&#8221;) (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation, but not later than three months after the Rights Determination Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the
Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash,
stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<U>Distribution</U>&#8221;), at any time after the issuance of
this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon
complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that to the extent that the Holder&#8217;s right to participate in
any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as
a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company,
directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is
completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv)&nbsp;the
Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off,</FONT> merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding
shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other
business combination) (each a &#8220;<U>Fundamental Transaction</U>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section&nbsp;3(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or
acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<U>Alternate Consideration</U>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of
shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;3(e) on the exercise of this Warrant). If holders of Common Stock are given any choice
as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise of this Warrant following such Fundamental Transaction. In the context of a Fundamental Transaction that is an exchange offer (i.e., a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">stock-for-stock</FONT></FONT> transaction), the Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<U>Successor Entity</U>&#8221;) to assume in
writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section&nbsp;4(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
(without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar
in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (reflecting a ratable adjustment
to the exercise price and the number of shares issuable hereunder accounting for the exchange ratio in such Fundamental Transaction). Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall
assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Calculations</U>. All calculations under this Section&nbsp;4 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section&nbsp;4, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and
outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Notice to Holder</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this
Section&nbsp;4, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement
of the facts requiring such adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Notice to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall
declare a dividend (or any other distribution in whatever form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the Company shall authorize the granting to
all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection with any
reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register (as defined
below) of the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of
the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery
thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT>
information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> The Holder shall remain entitled to
exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;5.</U> <U>Transfer of Warrant</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Transferability</U>. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such
payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations to be transferred to such assignee or assignees, and shall issue to the
assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The acceptance of the new Warrant by the assignee or assignees, as applicable, shall be deemed the acceptance by such
assignee or assignees of all of the rights and obligations in respect of the new Warrant that the Holder has in respect of this Warrant. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of
Warrant Shares without having a new Warrant issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>New Warrants</U>. This Warrant may be divided or combined with other Warrants
upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with
Section&nbsp;5(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such
notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Warrant Register</U>. The Company shall register this Warrant, upon records to be
maintained by the Company for that purpose (the &#8220;<U>Warrant Register</U>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for
the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;6.</U> <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;3(d)(i), except as expressly set forth in Section&nbsp;4. Without limiting the rights of a Holder to receive Warrant Shares on a
&#8220;cashless exercise,&#8221; and to receive the cash payments contemplated pursuant to Sections 3(d)(i) and 3(d)(iv), in no event will the Company be required to net cash settle an exercise of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated
as of such cancellation, in lieu of such Warrant or stock certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Saturdays, Sundays, Holidays, etc</U>. If the last or
appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Authorized Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its
officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may
be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the
exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and
nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Except and to the extent as waived or consented to by the Holder, the Company shall not by
any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to
avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights
of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and
(iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this
Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is
exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be
determined in accordance with the provisions of the Underwriting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Nonwaiver and Expenses</U>. No course of dealing or any
delay or failure to exercise any right hereunder on the part of Holder or the Company shall operate as a waiver of such right or otherwise prejudice such party&#8217;s rights, powers or remedies, notwithstanding the fact that the right to exercise
this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant or the Underwriting Agreement, if either the Holder or the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the other party, the party who failed to comply with the Warrant shall pay to the materially damaged party such amounts as shall be sufficient to cover any costs and expenses including, but not limited to,
reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the materially damaged party in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be
delivered in accordance with the notice provisions of the Underwriting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <U>Limitation of Liability</U>. No provision hereof,
in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of
any Warrant Shares or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted
by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the
provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of
this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <U>Amendment.</U> This Warrant may be modified or
amended or the provisions hereof waived with the written consent of the Company and the Holder; provided, however, that this Warrant may not be amended to cause the Beneficial Ownership Limitation to exceed 19.99% if the issuance of shares of Common
Stock upon exercise of this Warrant would require shareholder approval under Rule 5635(b) of the Listing Rules of The Nasdaq Stock Market LLC, unless such issuance has first been approved by stockholders of the Company in accordance with such Nasdaq
listing rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">l) <U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the
remainder of such provisions or the remaining provisions of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <U>Headings</U>. The headings used in this Warrant are for
the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">******************** </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page Follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized as of the date first above indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ELEDON PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David-Alexandre C. Gros, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acknowledged and Agreed</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">TO:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ELEDON PHARMACEUTICALS, INC.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2)
Payment shall take the form of (check applicable box): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[&#8195;] in lawful money of the United States; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[&#8195;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 3(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrant Shares shall be delivered to the following DWAC Account Number: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[SIGNATURE OF HOLDER] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Investing Entity:
_______________________________________________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Signature of Authorized Signatory of Investing Entity</I>: _________________________________
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Authorized Signatory: ___________________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of Authorized Signatory: ____________________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: ________________________________________________________________________ </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d28785dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELEDON PHARMACEUTICALS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant
Shares: _______ Issue Date:______, 20__ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initial Exercise Date: _______, 20__ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE COMMON STOCK (the &#8220;<U>Warrant</U>&#8221;) certifies that,
for value received, _____________ or its assigns (the &#8220;<U>Holder</U>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the
&#8220;<U>Initial Exercise Date</U>&#8221;) and until this Warrant is exercised in full (the &#8220;<U>Termination Date</U>&#8221;) but not thereafter, to subscribe for and purchase from Eledon Pharmaceuticals, Inc., a Delaware corporation (the
&#8220;<U>Company</U>&#8221;), up to ______ shares (as subject to adjustment hereunder, the &#8220;<U>Warrant Shares</U>&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<U>Common Stock</U>&#8221;). The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;3(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;1.</U> <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set
forth in that certain Underwriting Agreement (the &#8220;<U>Underwriting Agreement</U>&#8221;), dated November&nbsp;12, 2025, among the Company and Leerink Partners LLC, as representative of the underwriters named in Schedule A thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;2.</U> <U>Issuance of Securities; Registration of Warrants</U>. The Warrant, as initially issued by the Company,
is offered and sold pursuant to the Registration Statement. As of the Initial Exercise Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or
an exchange meeting the requirements of Section&nbsp;3(a)(9) of the 1934 Act as in effect on the Initial Exercise Date, the Warrant Shares, are not &#8220;restricted securities&#8221; under Rule 144 promulgated under the 1933 Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;3.</U> <U>Exercise</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or
times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by <FONT STYLE="white-space:nowrap">e-mail</FONT> (or
<FONT STYLE="white-space:nowrap">e-mail</FONT> attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<U>Notice of Exercise</U>&#8221;). Within five (5)&nbsp;Trading Days following the date of exercise as aforesaid, the Holder
shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in
Section&nbsp;3(c) below is specified in the applicable Notice of Exercise. No <FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder
and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading Days of the date on which the final Notice of Exercise is delivered to the Company.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to
the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1)&nbsp;Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Exercise Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was <FONT
STYLE="white-space:nowrap">pre-funded</FONT> to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.001 per Warrant Share) shall be required to be paid by
the Holder to any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind
(&#8220;<U>Person</U>&#8221;) to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such <FONT STYLE="white-space:nowrap">pre-paid</FONT> aggregate exercise price under any
circumstance or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.001, subject to adjustment hereunder (the &#8220;<U>Exercise Price</U>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Cashless Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless
exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing <FONT STYLE="white-space:nowrap">[(A-B)</FONT> (X)] by (A), where: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of
Exercise if such Notice of Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;3(a) hereof on a day that is not a Trading Day or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(2) both executed and delivered pursuant to Section&nbsp;3(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b)(68) of Regulation NMS
promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the option of the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z)&nbsp;the Bid Price of
the Common Stock on the Principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a
Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section&nbsp;3(a) hereof or (iii)&nbsp;the VWAP on the date of
the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section&nbsp;3(a) hereof after the close of &#8220;regular trading hours&#8221; on such
Trading Day; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exercise Price of this Warrant, as adjusted hereunder; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(X)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms
of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Bid
Price</U>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or
the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX
is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and
if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all
other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Principal Trading Market</U>&#8221; means the Trading Market on which
the Common Stock is primarily listed on and quoted for trading, which as of the initial issuance date of this Warrant is the Nasdaq Capital Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Trading Days</U>&#8221; means any weekday on which the Principal Trading Market is normally open for trading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Trading Market</U>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading
on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>VWAP</U>&#8221; means, for any date, the price determined by the first of the
following clauses that applies: (a)&nbsp;if the Common Stock is then listed or quoted on the Nasdaq Capital Market or any other national securities exchange, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Nasdaq Capital Market or other national securities exchange, as applicable, on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02
p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock is then reported in The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of
the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Warrant Shares are issued in
such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9) of the 1933 Act and Rule 144 promulgated under the 1933 Act, the Warrant Shares shall be deemed to have been acquired by the Holder, take on the
characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. In the event that the Registration Statement registering the issuance of Warrant
Shares is, for any reason, not effective at the time of exercise of this Warrant, then the Warrant may only be exercised through a cashless exercise, as set forth in this Section&nbsp;3(c). Except as set forth in Section&nbsp;3(d)(iv) and
Section&nbsp;3(d)(iv), in no event will the exercise of this Warrant be settled in cash. The Company agrees not to take any position contrary to this Section&nbsp;3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Mechanics of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Delivery of Warrant Shares Upon Exercise</U>. Following delivery of the Notice of Exercise, the Company shall cause the
Warrant Shares purchased hereunder to be transmitted by the Company&#8217;s transfer agent (the &#8220;<U>Transfer Agent</U>&#8221;) to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The
Depository Trust Company (&#8220;<U>DTC</U>&#8221;) through its Deposit or Withdrawal at Custodian system (&#8220;<U>DWAC</U>&#8221;) if the Company is then a participant in such system and either (A)&nbsp;there is an effective registration
statement permitting the issuance of the Warrant Shares to the Holder or the resale of the Warrant Shares by the Holder or (B)&nbsp;the Warrant Shares are eligible for resale by the Holder without volume or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name
of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the latest of (i)&nbsp;one (1) Trading Day
after the delivery to the Company of the Notice of Exercise and (ii)&nbsp;one (1) Trading Day after delivery of the aggregate Exercise Price and Notice of Exercise to the Company (such date, the &#8220;<U>Warrant Share Delivery Date</U>&#8221;). If
(A)&nbsp;and (B) above are not true, the Transfer Agent will either (i)&nbsp;record the Warrant Shares in the name of the Holder or its designee on the certificates reflecting the Warrant Shares with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
an appropriate legend regarding restriction on transferability, which shall be issued and dispatched by overnight courier to the address as specified in the Notice of Exercise, and on the
Company&#8217;s share register or (ii)&nbsp;issue such Warrant Shares in the name of the Holder or its designee in restricted book-entry form in the Company&#8217;s share register. Upon delivery of the Notice of Exercise, the Holder shall be deemed
for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the third Trading Day following
the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the
applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the eighth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are
delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the DTC Fast Automated Securities Transfer Program program so long as this Warrant remains outstanding and exercisable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the
request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this
Warrant, which new Warrant shall in all other respects be identical with this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iii. <U>Rescission Rights</U>. If
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;3(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iv. <U>Compensation for <FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver Warrant Shares Upon
Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;3(d)(i) above pursuant to an
exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<U><FONT STYLE="white-space:nowrap">Buy-In</FONT></U>&#8221;), then the Company shall (A)&nbsp;pay in
cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the
number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the
option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such
purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in
respect of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or
in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">v. <U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be
issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction
in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any
transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for <FONT STYLE="white-space:nowrap">same-day</FONT> processing of any Notice of Exercise and all fees to the DTC (or another established clearing corporation
performing similar functions) required for <FONT STYLE="white-space:nowrap">same-day</FONT> electronic delivery of the Warrant Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vii. <U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the
timely exercise of this Warrant, pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Holder&#8217;s Exercise Limitations</U>. The Company shall not
effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section&nbsp;3 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the
applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates (as such term is defined in Rule 405 under the 1933 Act), and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates
(such Persons, &#8220;<U>Attribution Parties</U>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by
the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common
Stock which would be issuable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock,
including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitled the holder thereof to receive Common stock
(&#8220;<U>Common Stock Equivalents</U>&#8221;)) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in
the preceding sentence, for purposes of this Section&nbsp;3(e), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the 1934 Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder
that the Company is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d) of the 1934 Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that
the limitation contained in this Section&nbsp;3(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of
this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm
the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d) of the 1934 Act and the rules and regulations promulgated thereunder. For
purposes of this Section&nbsp;3(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the Company&#8217;s most recent periodic or annual
report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock
outstanding. Upon the written or oral request of a Holder, the Company shall within one (1)&nbsp;Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of
outstanding shares of Common Stock was reported. The &#8220;<U>Beneficial Ownership Limitation</U>&#8221; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of
Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;3(e), provided that to the extent required under Nasdaq
Marketplace Rules, the Beneficial Ownership Limitation in no event exceeds 19.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by
the Holder and the provisions of this Section&nbsp;3(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;3(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4.</U> <U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued
by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number
of shares, or (iv)&nbsp;issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares
of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon
exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;4(a) shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re classification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;4(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all of the record holders of any class of shares of Common Stock (the &#8220;<U>Purchase Rights</U>&#8221;), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this
Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if
no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (such date, the &#8220;<U>Rights Determination Date</U>&#8221;) (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation, but not later than three months after the Rights Determination Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the
Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash,
stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<U>Distribution</U>&#8221;), at any time after the issuance of
this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon
complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that to the extent that the Holder&#8217;s right to participate in
any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as
a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company,
directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is
completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv)&nbsp;the
Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off,</FONT> merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding
shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other
business combination) (each a &#8220;<U>Fundamental Transaction</U>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section&nbsp;3(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or
acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<U>Alternate Consideration</U>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of
shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;3(e) on the exercise of this Warrant). If holders of Common Stock are given any choice
as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise of this Warrant following such Fundamental Transaction. In the context of a Fundamental Transaction that is an exchange offer (i.e., a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">stock-for-stock</FONT></FONT> transaction), the Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<U>Successor Entity</U>&#8221;) to assume in
writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section&nbsp;4(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
(without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar
in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (reflecting a ratable adjustment
to the exercise price and the number of shares issuable hereunder accounting for the exchange ratio in such Fundamental Transaction). Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall
assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Calculations</U>. All calculations under this Section&nbsp;4 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section&nbsp;4, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and
outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Notice to Holder</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this
Section&nbsp;4, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement
of the facts requiring such adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Notice to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall
declare a dividend (or any other distribution in whatever form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the Company shall authorize the granting to
all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection with any
reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register (as defined
below) of the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of
the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery
thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT>
information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> The Holder shall remain entitled to
exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;5.</U> <U>Transfer of Warrant</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Transferability</U>. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such
payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations to be transferred to such assignee or assignees, and shall issue to the
assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The acceptance of the new Warrant by the assignee or assignees, as applicable, shall be deemed the acceptance by such
assignee or assignees of all of the rights and obligations in respect of the new Warrant that the Holder has in respect of this Warrant. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of
Warrant Shares without having a new Warrant issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>New Warrants</U>. This Warrant may be divided or combined with other Warrants
upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with
Section&nbsp;5(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such
notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Warrant Register</U>. The Company shall register this Warrant, upon records to be
maintained by the Company for that purpose (the &#8220;<U>Warrant Register</U>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for
the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;6.</U> <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;3(d)(i), except as expressly set forth in Section&nbsp;4. Without limiting the rights of a Holder to receive Warrant Shares on a
&#8220;cashless exercise,&#8221; and to receive the cash payments contemplated pursuant to Sections 3(d)(i) and 3(d)(iv), in no event will the Company be required to net cash settle an exercise of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated
as of such cancellation, in lieu of such Warrant or stock certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Saturdays, Sundays, Holidays, etc</U>. If the last or
appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Authorized Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its
officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may
be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the
exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and
nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Except and to the extent as waived or consented to by the Holder, the Company shall not by
any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to
avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights
of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and
(iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this
Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is
exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be
determined in accordance with the provisions of the Underwriting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Nonwaiver and Expenses</U>. No course of dealing or any
delay or failure to exercise any right hereunder on the part of Holder or the Company shall operate as a waiver of such right or otherwise prejudice such party&#8217;s rights, powers or remedies, notwithstanding the fact that the right to exercise
this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant or the Underwriting Agreement, if either the Holder or the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the other party, the party who failed to comply with the Warrant shall pay to the materially damaged party such amounts as shall be sufficient to cover any costs and expenses including, but not limited to,
reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the materially damaged party in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be
delivered in accordance with the notice provisions of the Underwriting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <U>Limitation of Liability</U>. No provision hereof,
in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of
any Warrant Shares or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted
by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the
provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of
this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <U>Amendment.</U> This Warrant may be modified or
amended or the provisions hereof waived with the written consent of the Company and the Holder; provided, however, that this Warrant may not be amended to cause the Beneficial Ownership Limitation to exceed 19.99% if the issuance of shares of Common
Stock upon exercise of this Warrant would require shareholder approval under Rule 5635(b) of the Listing Rules of The Nasdaq Stock Market LLC, unless such issuance has first been approved by stockholders of the Company in accordance with such Nasdaq
listing rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">l) <U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the
remainder of such provisions or the remaining provisions of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <U>Headings</U>. The headings used in this Warrant are for
the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">******************** </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page Follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized as of the date first above indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ELEDON PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David-Alexandre C. Gros, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acknowledged and Agreed</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">TO:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ELEDON PHARMACEUTICALS, INC.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2)
Payment shall take the form of (check applicable box): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[&#8195;] in lawful money of the United States; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[&#8195;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 3(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrant Shares shall be delivered to the following DWAC Account Number: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[SIGNATURE OF HOLDER] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Investing Entity:
_______________________________________________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Signature of Authorized Signatory of Investing Entity</I>: _________________________________
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Authorized Signatory: ___________________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of Authorized Signatory: ____________________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: ________________________________________________________________________ </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d28785dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g28785g1112131230292.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">O&#8217;Melveny&nbsp;&amp; Myers LLP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">T: +1 949 823 6900</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">File Number: 0241090-00013</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">610 Newport Center Drive</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">F: +1 949 823 6994</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">17<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">omm.com</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Newport Beach, CA 92660-6429</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;12, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eledon
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19800 MacArthur Blvd., Suite 250 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Irvine, California 92612 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><I><U>Underwritten Offering of Common Stock and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants Exercisable for Shares of Common Stock of Eledon Pharmaceuticals, Inc.</U></I></B><B> </B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Eledon Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<U>Company</U>&#8221;), in connection with the
offer and sale by the Company of 15,152,485 shares (the &#8220;<U>Firm Shares</U>&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<U>Common Stock</U>&#8221;), (ii)
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the &#8220;<U><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</U>&#8221;) exercisable for up to an aggregate of 15,151,515 shares of Common Stock (the &#8220;<U><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares</U>&#8221;) and (iii)&nbsp;the grant to the Underwriters (defined below) of an option to purchase an additional 4,545,600 shares of Common Stock (together with the Firm Shares, the
&#8220;<U>Shares</U>&#8221;) pursuant to that certain underwriting agreement, dated as of November&nbsp;12, 2025 (the &#8220;<U>Underwriting Agreement</U>&#8221;), by and between the Company and Leerink Partners LLC, as representative of the several
underwriters named therein (the &#8220;<U>Underwriters</U>&#8221;). The Shares, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are referred to collectively herein as
the &#8220;<U>Securities</U>.&#8221; The Securities are being offered and sold pursuant to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-282260)</FONT> (the
&#8220;<U>Registration Statement</U>&#8221;), initially filed by the Company with the Securities and Exchange Commission (the &#8220;<U>SEC</U>&#8221;) on September&nbsp;20, 2024 and declared effective by the SEC on October&nbsp;2, 2024, the
prospectus included in the Registration Statement and the prospectus supplement (the &#8220;<U>Prospectus Supplement</U>&#8221;), dated November&nbsp;12, 2025 and filed with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our capacity as counsel, we have examined originals or copies, certified or otherwise identified to our satisfaction, of those corporate
and other records and documents we considered appropriate including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Prospectus Supplement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Underwriting Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Restated Certificate of Incorporation of the Company, as amended, as presently in effect (the
&#8220;<U>Certificate of Incorporation</U>&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Amended and Restated Bylaws of the Company as presently in effect; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Austin &#149; Century
City &#149; Dallas &#149; Houston &#149; Los Angeles &#149; Newport Beach &#149; New York &#149; San Francisco &#149; Silicon Valley &#149; Washington, DC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Beijing &#149; Brussels &#149; Hong Kong &#149; London &#149; Seoul &#149; Shanghai &#149; Singapore &#149; Tokyo </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g28785g1112131230292.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">resolutions adopted by the Board of Directors of the Company relating to the registration of the offer and sale
of the Securities under the Prospectus Supplement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our examination, we assumed the legal capacity of all natural
persons, the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, conformed or photostatic copies and the authenticity of
the originals of such latter documents. To the extent that the Company&#8217;s obligations depend on the enforceability of any agreement against the other parties to the agreement, we have assumed that such agreement is enforceable against such
other parties. As to any facts material to the opinions expressed herein which were not independently established or verified, we have relied upon oral or written statements and representations of officers and other representatives of the Company.
In addition, we have obtained and relied upon those certificates of public officials we considered appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of such
examination, our reliance upon the assumptions in this opinion and our consideration of those questions of law we considered relevant, and subject to the limitations and qualifications in this opinion, we are of the opinion that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The issuance and sale of the Shares has been duly authorized by all necessary corporate action on the part of
the Company and, upon payment for and delivery of the Shares in accordance with the Underwriting Agreement, the Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have been duly authorized by all necessary
corporate action on the part of the Company and constitute the legally valid and binding obligation of the Company, enforceable against the Company in accordance with their terms, except as may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws relating to or affecting creditors&#8217; rights generally (including, without limitation, fraudulent conveyance laws) and by general principles of equity, including, without limitation, concepts of materiality,
reasonableness, good faith and fair dealing and the possible unavailability of specific performance or injunctive relief, regardless of whether considered in a proceeding in equity or at law. Upon the issuance, payment for and delivery of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares in accordance with the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares will be validly issued, fully paid
and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion in paragraph 2 assumes that, upon issuance of
the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under the
Company&#8217;s Certificate of Incorporation. The law governed by this opinion letter is limited to the present law of the State of New York and the current General Corporation Law of the State of Delaware. We express no opinion as to the laws of
any other jurisdiction and no opinion regarding the statutes, administrative decisions, rules, regulations or requirements of any county, municipality, subdivision or local authority of any jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> promulgated under the Securities Act of 1933, as amended (the &#8220;<U>Securities Act</U>&#8221;), and no opinion is expressed herein as to any matter pertaining to the contents of the Registration
Statement, the base prospectus included in the Registration Statement or the Prospectus Supplement, other than as expressly stated herein with respect to the Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g28785g1112131230292.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the use of this opinion as an exhibit to a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and to the reference to this firm under the heading &#8220;Legal Matters&#8221; in the Prospectus Supplement. In giving this consent, we do not thereby admit that we are included in the category of persons whose
consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations promulgated thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Respectfully submitted,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ O&#8217;Melveny&nbsp;&amp; Myers LLP</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>eldn-20251112.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/13/2025 6:53:23 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:eldn="http://www.eledon.com/20251112"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.eledon.com/20251112"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eldn-20251112_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eldn-20251112_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>eldn-20251112_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/13/2025 6:53:23 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>eldn-20251112_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/13/2025 6:53:23 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eldn-20251112.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g28785g1112131230292.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g28785g1112131230292.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  8 '@# 2(  A$! Q$!_\0
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JZ==#IO"6A_\ "/>&K2P8#SE7?,1W<\G\NGX4445A*3E)R?4VC%122/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001404281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 12,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eledon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-1000967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">19800 MacArthur Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-8090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELDN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d28785d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d28785d8k.htm">d28785d8k.htm</File>
    <File>eldn-20251112.xsd</File>
    <File>eldn-20251112_lab.xml</File>
    <File>eldn-20251112_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d28785d8k.htm": {
   "nsprefix": "eldn",
   "nsuri": "http://www.eledon.com/20251112",
   "dts": {
    "inline": {
     "local": [
      "d28785d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "eldn-20251112.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "eldn-20251112_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eldn-20251112_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-11-12_to_2025-11-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d28785d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-11-12_to_2025-11-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d28785d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.eledon.com//20251112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-25-278392-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-278392-xbrl.zip
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M4R:U:K/16J%K.6EK!W@N$1$\3K'2X#Q^$CC+56B6Q>>I5M>:]</Z\G=4US3
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M,Q8!F>APJ8)+J>:WD]LR4EOXS?9<W[!_KD&_'ZNCJ1JZD"&Q>: C:6"M[?I
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M2@3-4>I,\3U\N@D/&.8&V!8,PT2B$YY! (D_4;U'S%.N-[[!QE#) P#?&RC
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MS2VK/ YAK+S=7$>%J'F'/0:Z%CM@X0RK\0^>_<"&JX<QGGT6 [T4S3M/_B^
M2^.5X=(P</GT['3LWRZYYBM+KFDD=Z52O1N3ZNV8WCUL!_ZUHK2JC1>480>8
M+<!4CA@84#!]5&^L7M*0$K5/?(BR<!RS 6KJ\CWEJ G^';UD0P /NB<N]<%K
MT/IM^>\Y\Y-SYC=]26B_]\OUQ?WO=]W^B]>/;E<V<DW)6.>1N]WF*&XZP>]$
M[H+8-)+*QW-I_J@'3C. @ !6BR=Q=(5QP,;4'<8G#5208!I@<!#A'J\:#F0S
M]@4LS'FH6O3-IY6KB606U@V5*^Z>6N:^F'?'83;W;NZ)B$:2WZZD"*_V;M3=
MKD$_[EV=W\R86_Y(R5,# =3!G$A /<J& OMM]H:OV=5_X*B=$UV]S%N%]SS@
M^<^+]LN\O_:Q=YNW7"5ZI)NKR H$7%/NE"Y<-H<45C#2*9-?A ]@_UR^++_M
M=>9OS6S@G=J]XT3A;XN0W@6T&\O5)?>7D5!GS-EP[4W(8E-FLII2G%7T7\96
M?S3[_/\!4$L#!!0    ( /"F;%M._0G# -0  %0N!  /    9#(X-S@U9&5X
M,3$N:'1M[+UI<]O(EB;\G1'\#XB:[@XI O:5O-7B:D?(6UV_U^72V*Z^T_,-
M)$$)91+@!4#)ZE__GC7S9 (@J<VR)SS1<\N22""7DR?/\ISG_/KWC[^_??;K
MWU\=O7PV'OWZ\<W'MZ^>O?H_]P[O'_[Z-_X)?OTW^7ORZ_,_7OYW\ORW%W^\
M_>/]?_[PS[^_^?CJA^3#Q_]^^^H_?U@497[O-"].3MM?WE7U,EO\\"P9C^#[
M+_*RS>MGO[Y\\U_ZX?-BUI[^\M/]QT7Y0Y(MBI,2'I#/VQ_H-<?ZL656GQ3E
MO;9:_7*P:I\F\O.D:MMJR;^:5V5[KRG^)__ET/\\SY;%XN*7C\4R;Y)W^7GR
MOEIF\*:CMV]^>_>?/]0XR!^>_?K\V:O/I\6D:!.8</+KWYX_^_5OQSCCO@$<
M/KC!$4QI27YX]FJ1SZHR.3[-8,&F^;HMIMFB29,WY?1^@H/I7XPGMS"4O6P\
M>IDOLO.LSI-I5:^J.FN+JMS_PN,X?)P>/GZ0/OKI<?(!E@4^6\V3%]5R">OT
MH:VFGY(-FW0; _KU]1_O/CK!/2W:_%ZS@LWZI:S.ZVSUP[/C.K_W>EW.\ME_
ME)-F]?2?65UG9=O\^C?\YK.DK9+C=3T]S9H\6:_P1YKC8?KX\"ISO!5!A+/P
MY[N7K][_\_V;CV_>_98<_?;^U:O?7\'$O^2QD(/YKCK+EY.\YN4\?) F#PX>
M/-X@AS<RB&=O\[PNRD_)<5:W95XWR=NW+S;,_"8TTK.L2=[G*Y  V <X;F<Y
M2D)[FB=-?I;7V2+Y$^2J/J]!ZF! M[T"T[]5B:S">!0OP^WIY6>/'X+89VT.
M_UOG>9LFCP[:T^3UHJKJ#7.^D5<_KYJV*M/D]Z/DX,'AP<]XW]VRF&6S GZ3
ME;/D-]CU1;[,RU^NH&3;_'-[KP#Q*-M?'OW[)0?!%P]L<M_-DR99TG<5)'LH
MF?_QOWYZ\.#@Z:]_/@.-M<K*BU__]N<S^N7AT_T4/E_.BWK9)$4+DSR!_83Y
MM<EY 3O:=\+XD._YI\8?"A^/RY9GTU,])Q7\3QV>DC);YK.D@-G!TSY,3_/9
M>I'C4^!'^0^_] A_2N#[.>CDO6FU6.13/(.+BS0)9VJ?CU]*94 )W <P%OCU
M,FE.L\4"C)FF@G=/%^M9#H.]2-;^JTFSGC1MT:Y;&!^<?'QS469S_-.JKLZ*
M&8T[^8##J$I1?P?TN6H.DY_#>> W=E:R@,6&;Y4G\.#QJ YURAX\M%G#UZ89
MW%Q%VYE?J(/"%:>=@[^N8%1X>>T5^SPR4E/9(D\F%_0X$0?:(OQYI9>>_-TN
M8JJC%3VWX*^559O\515P*F"(LL/R:IQ'N<9K@6[+AN]-*Y&O0>QXS^EO=A;X
MC2G?KPW>KVFRRNKD+%NL\^3?#NX?'!PF*]P?_*)[L<YG+Y!X=T=WY7*KI0"+
M?&].EH+:!N=B*Z0L&_#/@A8#-@R' !N^Q.' J]54?6Z$-L7]T&4>CYI^6R(Z
MM9>P9W24WJ)Q4^89M]5)3@>0A 3?@YL@1DTL9&_* F>'XKT&*2C"+6*9:O(6
M)PT/@Q78Y?B.1[H4.)Z]P@KG"0XZEDY8L6L(8[4B13C+FVE=3'J.ZX.]R;X<
M6+LY">H&.+TX A"]%I_W*'W\Z''ZY. @R6:S A\!B[-A#\<COY9_\#@ZDHX#
M3WNVI;OV\>[T[\K]Y&.XJ;0RP=L3O"58E8%^ 1TZPTM@6)?Z,=_70>,[^B<^
M'A5-L\XF"S2=X9?YY[R>%HTSDZXAS&;<K(+K?)[7=8Y2C=HY'+5\*^D9_56L
MXVM=WA^-.-/U@HICAB/.VHYPX\VRJF#%8%;+[!-((@CE9%%,80GG>(F<Z%IZ
M"<#I-Q4LMRQ#9*+.X$Z'2R:;G14-;0VO7WL*EY![-3[XR%W_>_1'OYSN+X&6
MAI.23/*<MGG*MR1(VRQ?P%MA8S:YQ+>_TCBX>0'B/1ZY8V67#$;ZZC,<]O*$
MOK,$P>VWF>0OP<PSD/]\,0<9/"F:5LRM!FUB6C[X8:NDOX:[@G70AWL/5=CW
MWE7WMW_UX<.']Q[ 2)X<[*?Z3;9AR* 8CT"&Z!)>-_%\GJ-R.W9_CFW!,Y8P
M4ITJ;KA29#?@I9S7;8;6B=%+_LWA$J<L[/'"'TU)FQ[^_/!AB@(+UA\>]WB@
M^'?\;+CL8JK4<,7P%L(&K!>T_*B+QB.Y.G0W82&6Z\5)AK*)&C;G(0V\"PZ.
M>UID5)$5MW'/SV$NLWRZR% EY;!X; /!9_Z8MI5SC]D[?G0_^8 &7O^S:%U@
MC>C^ QE/DV6>P02;X:_ \?9+.;G@BPM\I7M^)/17_&S#2X$W:\7/Y)>$&YFS
M </+C(]KY&[W7P?U9;Z.7YI5TS6_ AXFG@@,"&Y25$*LJR=Y^$<8+:GRO)SF
M_&@0,/MH]O'P?U^^^2^P*21 .1XE]'^_KF 9+A9YJ%_R94>]X*]6V4E^;U+G
MV:=[DQPLE_R7;'&>730_@)[ZVPI?\O?WR8<W_Q=.WL,?]+D40/WE?_U,_^^'
MY)]O7G[\^W_^<'AP\.\N%/+BU;N/K]Y_=2%4>#B8-' CE^0+O %A20X?H&RA
M^MFN:8QJ\H?9'1<]CG[7R;T[QPL_V.^,C:A6#"V6;K>_B1WB>Y"PY-'#@^?^
MA>-1WP&U=K[[4GAJX0JS1H**5FPKO+<GZH.>*'S44[49U-U+D]/J'*W.U-_>
M\J#^ISC'$ZZ@:MU:28?SP],?.-S@(#CE<I7#S:N,(Z2WR+_!V6]:]/KA+:R)
M2;>CJQJK;W&6\<OL+$\PO% VL! UZU.=>PD"Y\<R@U'KO'6?AY1FY*S2;IO+
M O\NOA6NDE@_($P9. NKTV1OOK_W@-Q%)P(;]5B/#@ME<4<U=CD%EFP_@S#K
MK^D4DA6I*WH_.2HOAG:03*R>$_R$/"L1NM[S6S3L##H_)#Z6YCG#1S1PI-BP
MI2G!N$ ">#LIWK/3,64YUWB07X5-H[B?O,( %YC<BV()SDE]D1C[JUFO5@M>
MJG4C<2XX1"4[H=[C&[;N0:#)%(@%^\;NVMN[(2+7ELVSR 1-$PY;>@]T0&EG
MNH7]*^W\.WCT<M5B4$#<G%S\$UQOXZ!<\%+#)>&\FS0(/9P7( OPLA4.$+^(
ML@[#F!?H^??OL9R=:(X8X4.QQYVK8H,89S>%/9IEN"E.(.C*:<2P%3%\\ C%
ML$<';+P7Z5O=*,&&::1!0(NOC/FZ+@NP@$G"EAF&2\^R8D$.94^0AFZ4-8:Y
M\'Q?5N"_<4'G>^RJ@F[4X'%7O&&T.!&,$31]$HP*S$V]<<J\5W6E;$KTGB<^
M"WX &@YSE@;^(I1\_+,Z86A;GU04I5/;P>^65;#3:G4AMXB3#>O!F3W#6_P5
MKEY=E<4T>9FU6?);AJM.JOX(Y/FB*?BF?Y^W=9&?88CNHL&]WI/QP^T Z]+@
MX.D/^_; O'KYV]'[\*A\\7#14:,W1;2WOUPEE2Z_0E>#AG*MH<E"'<&F%U,Z
M^?@1E4RV8W_\Y> @.;K_^_V4OOG?5?TI>5&TZLG"E@[DBRNYN3E%1"9))BDI
M/,_.MP^2%F&HZRH@C-M8H-_RDK+!+XMFNJB:-9S[XVSZ"7S/<*UP)F^:9@WS
MU:_\"3KC-4PY^2<'Y<8C?P3QLL!/S]"Z1#50%VBV\PF/-H6/[Q*\!- &"!L8
M,E#V3.0(AC.@;%6%6KVZSSX0B.@,=4LQH1 @'>^SO&DK"F8.C]#M85'B-<.J
M230#:/?M^<#G^LMMJOO>H6CN(!>#6LFZ,Z+ -Y[X+RE$(AA6&(PZ[@J2?*W@
MK\WQ:QK8-5K=V<L8K0(3@!6-V/H/G?K>T>-^&#G<3I34WT6):S,QO=P8!P:G
M8]OK&]S!XXW>1&=L!X_MV/:3#1:8B/%XY'*E=?ZO=5$[TV+X>@JS5:G):#ES
MM:XR<#Q/JW,RB;+26SYZ?#):BS8O*>FYAKN-)F5C!UTG6'=@;[:_]],^C!P=
M=C9!X#68#-MU$NEX!-^ D>O0P5P&"QI$J%J*'[7U:K:C>8RC@3=.,U!9<&E3
MM"$K4$PE$\?YJ&X> X:AB;M@C685_)&G-%]0J,#9K^C;D<7(,(,IVERA\;I@
M6[%O-4QJP,RKJLGE&EK"T#@&79*IH!I)P+T[_/$I!J#0M&_Z%^MDLWUQ!]IF
MZ!K:J'DV:RHGYD79<@@+S\$)OV@\<G<'+CVF8.6+&$GR%\F>6 6G<'[<R?KU
MS;-)5:)#-H,+XLVS)/?&H3MUVS3>7F;3(_BXU_ X:V>^QT=]@$<%"H6"]#E&
M!>$J)(<#S=-)3B8O3*"8%[O!6G:_QAYTKS&Q>#"&O!J((7<$*+$2\M.J_4$&
M<KO0K1C"^$!'_CVP?_O'^BU>PR".5SC6X]&V<XV*$H[E[AKD_J\?_G0+XV?U
MXV.8Y%E>$[;M'BWE+[!>M(/PA6=WKBJWGM"M'Y!=^0A:#9;D'NBT>__,&*4F
M)YLC#"]Z[(#QR&]-A2N,Z+(^NX$OZU4%?R 0B=>B%+AHLT\Y&MIH$144<ZHB
M4,QCN,5C8^NKN:C^*5.^_F9LVX7QJ&\;S &Y_2&$@K#-8-QH*8+]W(U;W45X
M(XQ/=:(<: .@:5=.479=HB'.W^!/;!-8]Y%35AZZ(I8G&&WN$*F;)(ZF2U35
M^AUZI?L]AHWX/6;0L*B+XA/8)TOPC]M]M?TN'V1+).UFM.J&<!G^09(;NZ\/
M!F #__IR^:P;G%JJP4TRTI?9!<PR#4,$NP;JGS(J88LH@2M;V<QH$+"\1FCT
M<KO&OLI"#J.-L?0#9!PJR2-E'EFD3+H9!D/HGU[0RR:4'[XDAMND5XVW;Y$9
M$N'K"0W'OUR"9SS:57"^/";MPZL7']_\\2XYO)]$R.VJY,T3K*) .>] )>]E
M^PGX4IO'%H4ZT-_B/)*&9!V(G;^I4&F4%G+-37;(8!,0+"  W)2WLC>0^6)1
M-7B"*'!HXT.3?%&=[SN0TDM\'#SZI4I ][-\?BBNS "#SO!(YN9P6JKSYNZ#
M[AA,V8A2@3_2E&R@F"7);L\RSQD<HD$-5H*2IKLQ.()DPV5W^P?M=LOGDA2.
MP9!2L&IR RCI>\N["DL#5J &9I3RAYF7'O.A7RWSIMDR%DX+@=8< -1$0T/3
MF6/P_CQHX*@O+UA6,D0X'&=HD.,UT!FP[,"EKISMXV%4/#YEFN?XKD9"D*(8
M*TS/NESB:0;3Y@>6KNRE^U!\0)TG.GH,ELE%&H>^/H' +/+924Y51K#<JT76
M^\Q04'%>( "@!#1<2><3I1:LY62/T1#[')Z,!D?3\^A\8_G<O?]RB7.Q31;I
M K3(+@P]A4)/CVIIZ<8CN;=#B%8?^"J"HO?A\@1RM1F$D/H=Q)PVF$9+]&[0
M8I47-CZD'.BC.,:OMD[?6S8B;^0V,0>FJW6B#';?XI+LG2N6O#=\?O=S]9A[
M!Z+KPV(DVZ 8.@"S:#AU##04;-YBN)/B,\YB=W%2*L0!F2Z;)?JF,\SL%XJT
M@ZGNEN.G#'P*CL T7[7>+6@I@YG7\FA0(7YM=KNS/M[72^M;C9@^_!XQO4W]
M_/$FH$;L^HQ'&Q1\[-^<G^;TI0M*F06&#]YF1A?1A\[A3?@'/%7L .%UO(MV
M(JN\H*PW_.;BZMKJ4:"MG!>**#=;C;'1/.)G= LQ'FTJQ+AS?,?'Z.X&G;-3
MP*!OW_5W/C9PQ6A$G];NT;+>OINM$1VY!@.PAGD+I!PA%_#GTVPQCRIJ_5 '
MINY-47JRJP:S>IV<?GVGL<CN<#,Q5X^>U=%TNL:C;. Z[#Z]RPO).@Y/O>S
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M!#+&K#7"!1(/ZD9S'O9,XY&-\);.?<H12C'O74%+QS$'(87%^=<:)IW73QE
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MP!"B7 ;CD5\SEHK.ELORT8KAYK[ YU=U663FVB4[)1 #!Z"DK(6,:NKR;1[
MK %U4B^H'5UCGG/8D^:T6%' %OZD/7E9!B[4*E4)"#(_$D ]IT@M&5Y@%A*V
ME5DAJO'(K!37UH;S/J=D&X>B799M>\@]SL,-)&"^"D7#D2UK+$GN-J-]DU]W
M$EY[N.=ID&9RS[CH=,KM<($[8OR>=[O@Q0;U13"'DZQD#%8O9_<&!6=/ N.
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MLF[5R9Q.&X]0?% U">8OE^O<VF*.%@1+7 314%>+4'X4^K"XX&KK0,MI%"Q
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M9><)R6W+##U/ABP+(1,5:;F-J$U!*NM##5#Z%6:&N,8ASG3'?'[!K[>M'G.
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M(+7\L&ZHW"-^>?N<0'N.Y?'(Q/#QA@X<E;U7?^)@GOSMR8\_[V^N2(J%P[>
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M[.&:_G=5?TI>4,L16.=]-63F1=VTR5Z#_ Q,0*AV&\65,+*-'@S=+H]^>7@
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MLLLGZ]@,,*$/20V=<6UG12+XKW7. +SQJ#K'JB9D6>XQ-E+?,U7S83IP.[J
MSGNZR-#Z<;+,0 IPM;'NDIH&,X F;]L%6Z:V(C3>,U.'V1A4$U&+<";#RUD(
MV> VT52B56(W<O(R7%*3NX>H^67FEH8;(:0KFR=K>^,)XS1?F4X2$CSEM.;>
M5\>8!D$>'-HBLL9EH9"^P-4V/?4@BPWG1VZ[B#T#%3Z;_T[C1SAX=![\;5#[
M?T>[E"W 7)K!/\_+P;N3^^:61@>IHL 4*]X]Q-G/5FXMRMJ11\.-W3J(.1]^
MAY@/E(%O#65(N.5B,W0\F$R>)8ZA&B_L&W9=GGHHQO:=0<E:^?9"JC:#CRK/
MHO6N'9()?=KJ(G>>+NW6O]:X$-B/J*0X%KB]I6?L5#&XY45X>=U%<%]*N;]%
MKV1$ZC?M73IBB0@Z/+CUVVK1E%5Y3Q=9;1I6J:B5Z"VXO'RG,45G@ME!%&I2
M'O37VUUK5'BOC.YPJ/.@[%COVH&[#7YXC=#W'1)9/[EB>61] )6)D28.IRXU
M?G\']MXG[$*,!A_Q4% +! _;ZJET&\S;''^-56<2PT5J()>Z-@\A\K;=4AI!
MM+"_*B/L 16&%T$ ^[#B]Y,C5PFEUD88F.;0H<W5!7T6Z ^V*"!:;P\4#.M.
MQB,NP7CRL&?M[D ,%TRZCKJM3EYCE^5_<HG?EI2K<I(3E9$P*:!"IV*&INM%
MD'F^R8W0 A("RBIPBUR'36+MV_F0C=@6V#H2+_#-,^([VGW56V/V(1K$H][3
M4OAHLJ2N;7' )M,JE[=N.]EL3MHCXZ9/^.GZ$/[IV!8R-3P/'_9!(#O8M*#-
M 8R$"B1E*WRV<MO^4VP/+[\---$[Q%!8Z3^_]T!4,G'S2 95<ZVRZ'65H8U6
MG2?:D2,S#NERN2XE=:6[8%0#=GX6$TW7:F^&)5@8-)*FJXUR V#WTR$X4BCR
MCBE!Q$[X%UJJWYM1?U9S*IQ T]\-F<F . 6;DAIH3_C[ >868N22I2MX,[>)
MK>F37)1NH13 X.?';0HE#-57Q@-6JD]T#A17/XQL']YTVQO3IXZT4V9\,,ZI
M>9.>*Z0B/]%V.F3&($DEA=N(Y)#J:1)/Q4V%[Q3Y"BJYMBD*&BG7G]1B_1$)
M9X)]Y5U_L1G\:U&M%+O4+4;A1JZ;7X4>_H*-1M2;JM3H=WY!;-?EH"?A)C/M
M,@6Q DO#@@DS$%]",1Y=HH0BF,P-UU2XBIZ=BRB((FG"D826Y"+M%+9THF.^
M\')#(;T>#5>,T%-70=%G<A#/2\+5E1C-VD4R I+@RC6%4_00BTC:4]KBZP^^
MW<S)@X/OF9/;H!=Y1/0BAL#Y%8MD<[?]?_PH>G.4V+T,3P"%ZX06"%GUN1B0
MO^J:G:MY VX"*<W2%PI8#AY/S#<>N3)/>S>Y0!F;M5@F)+P)8.,R&0$UB):B
MF8V(4A.\@LL7AH0*T"@W0IPZ&.OE@+ V=+MYJ!&75\14&(#M8ERDM27XCUNT
M5T_"?'=@G7YR6C7$/-I4TX)@$<QQX_!S8:2O)ZS=RXF+GBA'/RH,4)M ;&?Y
MG-D0\YG3I7,-(K-X4%;PI-*<H\HFJHM>49M]SOU*@@0M5_Y3LS4]7MNDN*P9
M0BB0S][90'5G+MM&YZE":'US&<2L:"9@%X4E?3'=KL#S4R55RU3B)9LP.RL:
MW@G[CFTD''Q^8XA=E[B< TP;F,L?[N7[KAF3/:=<.:13Q:?8@AX#T,?*G<$5
MV5AM$]9'MZY(0*K-^R@QC'RR"28.@&(EP1=;UV?YA;/X55:"4D]!T).9NG7L
M"(<\X>2*&P9]B6(B8%QI(N4,CU)J$@<8;(+5^;?#@_3@ !GBX2/[22!"3G_+
M$7:B#C<V6S,:#:Q[SA*(-;[5R(WHC.C)85391Q94#R1ABRBI18S=4EU3DCVD
M\RB'=FE)R!5S,7P(4D(J9)I_137;BLYQPX[UGL@Q=1S&] @F(YS#W"S@\N-Y
M$U*LF,*+!A<9W4MP5>@DYN4)+'48DXO.+\=P!J;JQQ"L88H["0X2O7]1S4ZX
M*B;<DI"'4+0"-X?L;)L(,I:5L@'L9K#7#8GH"]U-DM4ZGG@,_3TBR;[HN3V$
MT.7QP;^[:P $CM85?) ZF[=&M9$L8Y!(/+?3K&Z'>!&"I4SE+#FQ)F8KIX^,
MJ9/V*:?MVJ@/C=@=5"H/QG )+L;K-^_>.^X>[HFF)$K]*+WK:A@!-E@5LT6_
M?![4+T4I[OS XD=(-@-6NP8-NR>V;8?@;;R#>Y_M9O<H,6]"IKUJ@\C!LB4<
MY<9;!%QVZDV"GJDO\A-NPJY(BK7MWK[?JX5J=*&6AKS*=]6>*Q]65QBHC+C/
M(".[GOD]QR-TTGP%5]2AM1/[ /N]GOF4=0<>"_X%Y[COB#SG(S4O<[>U<S1<
M;63D@!#J0+XS2*=_^>XLC]/PYY]I7?9[?XL(B"IB[#+M*ON2)L623G5G9X=K
M HIM,Q^D-(.CWC,&(7^-6COXD7F\WX9CO/4#<.;N5?-[*[#-\]:%L_G$=_6,
M\-7.\GD&-Q6>%MM/&VDY+8UY$=26&=/RRPP[B,K>@JE[AZV0'PNEJFO<"4/M
MZQ/QAX\.>)Y5&S+0NZZOQ:*#O1"F,6P?.AYE&#[.IA?]:JW3DC2R?+S6\QP^
MJ,FCJEW)G5VUL_:F]K7N\'=#*U&VBE^!-YCRTGISJ)<"V15*L..N ?OYNJ;O
M^'ZKOWR[P<S#[\',VP@:QHRC_<$W'U,<2I0XS<<\'I*KI^8P0U_A7&)$7\NT
M.WV-4LKJ"S&GJFOO<IT"8.J#;.!U61,Z81._:G(%>M7.ZYE[?HCCM"46=U<\
MY>A\J0,#Y>4IJ4*=/61@1*4?]$-P[NHGN/8$=1R55$6YQ:>,M+/:*TA]>D)M
MI?_=8UK'_3[:X U,NSI2<Z=R\9K@-#?[97<1E==NVXXT[X6YVAT7.9ZKHQW[
M ADSS95ZX<>4F$]WHL3B",YN-W!EP@TS'BWREJK::2]FRF87O1,&^8?(P._Y
M L3Y@E7]?V3+U=/D]PN\I-^^/4X[5HKA^8M=4,,:^ %&4,)K_@%G=(&#^:U:
MS)H6;F/[FM?5Y^3X[=L7*1>>415K[]LZH&R$^RXPL(WN%Q("P>5^,1Z! '$
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M)PS_]JT\0+.=T*W9U[[Z:W!6-UPGWEX66NUBLI9[B9MKZC4CW2&MU24ZIF-
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M\6(:>[V; AXTDJGJZ_\U0- 6F,EFV/J7OU[>52T:.1AM=^"OL%]?CZ 0U7.
MHO#U?1Y9;WRP#-NCBISC-?]Y:ABG>\T'X:=U3,NAM4?K;0<P8+;%;9DU @./
M*%K%M\D@74DXVPW?<'CTR??PZ,T>$<7EGZR+!0?4YG6VGJT7>*9!0*-FH'N[
M(',.]^;[U);!HG/V_4G*N5=[>)+PZ2XO+H-"@-"Y,&GZ =()V33*+Z]J7J->
M%DYVF7F/9MFEDNS6"\GH(PZ29=[F" J.?.D=E7R&)7$F;.I=/2Q*:"AV%NRG
M%NX%U7WNW0HOZQC] C;K93.X2<Q9^. KKG7$*M:SV,,KUCD 63 F-J?ZVF8:
MW]I6'X<WTS8KE9IF2IUR4=KXD]P6Y7HYX1UX X8_^B?FT@&WDGI2H%\)SD%3
MM,HP: 979DO.Q?_ZY[,/T],<3^Q6#E7N@- F?U6%!J2_Y%G6>/1/%(]^'_(6
MI./1/SV-(8[4D],2:(4KCH78@QKU1AW:S\.OFS8:435B'(/LZ3XZU+:]&FX]
M2C3/;=#MEY=='68IB49*-$])4!!G14^%M+!!+\3F\6'&CN6JG:C[$KA6YU5,
M(6J4$ $UK Y*[1TAAWFA",1.);%?I-HP[\H2]3RD#7W'\<@DMY470)!>J^R"
M=D>!,7=)KJQB^S.)[3!=PUU6D)M1V0ZA :D!XM\<\T$2$ST,41ZDFS@/Z'.&
M]P"W- CGF\X_#J;FL#"5-H\)(6V^*95V(-G0?61K%RL+9[FE)E862O_5=+':
MW #M)II8$9"QT\6J)Z<C0E!-Q;??887\LG!-K@.*!<WN%+6, ;=:.8R[WQW8
MDVK=DH."XS^M0)\NE#TYR9MIMF!A:'VW-(GYXY^6 J29XM(XG2=SH"#$6;ZH
M5IR5IZ9XI$7=+J&$^AG_>?_#?=YQ.X]5A0."MT52DL/F@>\_#9A[@C@XB0W?
M(E[ZQ6)DI! 5Q!;MKF=R/"J6%KM,8X5U+!K-]DKLQ((JE_]_>]_^U$9R[?\[
M5?P/4YOD%GQKS )^[-K>N$J O.8& U_ <;92J5N#-(+)2AHR(X&Y?_WM\^H^
MW=,C"?.R$[8JL0W23#].GSZ/S_F<BV&NR8Q=\H'(C<9TY>$-D8'@BK*/TP2)
M:&G9JJB"GG'!F@';/P.V%12WE:*8C0(?0^5SM%F3\3EH4-&6#3RFR^:0&*8X
MO)9 ^_YOQ]WDXU].1&:E-Z019:#G[GYQPL-[$F\2L>A4<&A&UQ>CZ8@^\07_
MB@D-7FL>JV(+*K[0-Z&LFCZ/'1#H\_Q5]W$)W*0V2FI\2 "+Y#R;FB.H5(CM
M-L66KU&G![&J4.GX,;?IY+RLL'0$5EH66@7V^\9'G1++CZ=D"L;-5WAL3K/Q
M[])9S+.T+6 '#O;0Z%KB',R-L=G+V[5."./<AJ_6$%;&Q>Y.S7& 'R7U=6WN
M$GP0_/ BYXDH*<[LZ$;0%M1,URR[W>9^WAMF'!%E8OCWW _4/,A*D2Q4\3B=
M/*C%\IX+05N45W!=FW\H]J4V1RIMIT-*YK(A4=_S&],AD9XG!]=!8*859[#F
M$B2EP(Z$)$D_!21)7T^0]%U&$G]ZBB3>A_NQL8[^QTY.^5RC#@[&>%U\A-Q\
M!#5B05XE?6[D/K>\%&%1!$APE*D2 <,-!K>0<TU%,&S)#=UUUQ@0X7 *!2?M
M-X59R@<<P/,<OPI/&12P?8=/L-(T6<+8$(:%4N)2,V=N\P4=C7.P8,G&0VAD
M:HTCK_?/ 'WK<!63N?UVQN7X69]&C^T]L.U.F&'7E]_4^U70)(*JM\ BYZK2
M;$P_YN'$UDF /I))09>(J\,P0M)W-7N6PI+@F<Q69%$.;Y-BX-7=M*RY!5:R
M"2BX2F]%>1_P%W.7<?/%,]@H6;\+<_.7?8+TO?D&Z!-6)='LPGK1K; I8KB/
MS*\VUO]D@<+VF^KS;;SCV-928KF$3[@#270WK#VIJ:YTUK'#X77:./]XC7&Z
M3IPF-I\T2DF8<OUPII?.TX%75T.H\#I!PRZ?)A(+E^[J9#XZ%5PH7)@#B4H7
M"55]2ZEJ1%?2:,E2"Y\G6M^+<GK&[BPM51:2Y+I- +(G!XT'WYO=U0$3+  W
M;F7KY_(\&Q&+&)9CB_,1(_/V@O4(YOE^*:5Y1-W;9G;;0#75TR)\PT[%BR5C
M/M$ME _:1H8#^MXC3-9KW*1K2'E((5Z'ZXPAAN 9Z;%08Y,+=QZS+;,O>,?@
M)@.XR8&Q@*S@N'!H-$Z)&^.C50W(;#PWN.J],)]^I^XV9PTO'&593R[ B IM
M2V]TBQ'F8N4!VP'J1L56RHC\PM(1CTJ;&W",KQW<1&(4=Q$#ULP)$$O@D%1(
M/0[C5F;06M*IH;>YM.=*K?DEYF^01J:& +92T:99D/V:FY13689W7)65[>==
MUQ^Q+&5C QV:?<PZU"ZQ1VD(IFG']8- SG3,]2EUK >966ZQ!ERS5 ^3YJ)6
M_:DQ9SCZ/X! 5S%D#)?9F%J5$X T \0IJ_JV8^4$RM[U<-82GH#D0^(V%>7'
M:"A[.<1!?T>NB3%B)B?)QO/UC:1CQC2UWD5G9#YFQ#Y-7OYR_,GNCUOKGUZ:
MI;^$S&4O&SY##_6-V;8?WDW.?_G1?.-=\GY8@M*2*)'ZV_*2<88W7D-V!TMI
MI3W4%.ZZ(S.I[-IL5F-R_BD/YM4UZVB><P@%/N9*G.*XS/!WQ[VU--EX_?/Z
M>O(QZW6,+S&MDJWA9=_\^'@*^>W-E^OF<]5E <VIMCO)Z\U7&YMITIE,C(6_
M55T;>3XV.W/.U@BTE;Q _;98LZQ7&^LP=3!"H3<;N/K)3H79IHV?;K^X\-QD
MBPB1M\U'C;",BPPF\6I=)G%\GH,9_2&_[D]_?\Q3M\FG+NE _!Z:JAC1?U_T
MI[T":#./<DI\U.?%!9U)#_+;LZ!FE65GJ]YR[Q @3EU**J*_8&V0IK^!QPGF
MU[L("P9/S +MAWV4Z0:@4LQ6W&"*]_=XOK5G)%W0/<;D'Y^!<)#%YX+/YAX$
MQ<(6V&D^N0(MY*586\'X,;;[:!W$RJDK%KMA+8J%LT,*IZX3X26>"'PAQ#/1
MXO1=C#JCKM/&W,Z)\B:#_J/21P43D+6M[D>D <C<P,I<"%-J@UC05>M[CMC=
M%.H*<65ZYEXOF%AK=#$LK_.\]B,L7&FWTN/U"D"I,"?HQ#6B*^&JP$HG^#>5
MUKLCXX8/HX%\*AG#U)8BNVS KZ+=J6?L"QL6+=MBS*]*@Y4&-FO;P+GBG&#D
M-">S%Y@C&2,_$?P\!&?,0+G X<.W<$N_50X,>!%%>B,\P=FNP05RP[6P?0I\
M6%;^!8S2>GBM:G$:$!^SV7VEF&*E'+Y(*89\CI29DYV=4=8@2TZ!P)GR8A1_
M<:=;:L0QX\MYZ;R>\(_[!4Q0JK&XFTR8JE_)V\9J>[_;[ 0"VP%4GTK! <+A
MJ_QL.LPF+*>3[ ONLE0N+[[HH3O!#=FI@M"(.=/WJ)6;/1A\'H^F+BMK5#A:
M*#;75'WF=YP'^?DI#W(O!LQSA@]BGVK/+P88Q3%W+#W*S75$H"%P[$;B833[
M.F.=@=9>=(:!@VR[I/Y=72H0.@73GZ!^0@^<Z:H1<DJR.0-A)P^TAE4'#9W=
MB#ZDUGH1K4(.DM.PU(4@EE!)Z1X[%50('%6_G2FSH];^T*Z$X,=]S74"F3U)
MBEK&)\"%/=%9I%2@12  !\@89E>U"W\$R7@FPHG^_K$#4):1=R$!P\EL?=A&
M=+,%:EIHOG[&@K)H)'N.,$I"\8B T]&$' Y8[D+N>N[8"!MC@W2?J\RGR*S[
MV@0X!Y,SK)>J%'.QQ&G]\5B2*?> N3((S-)Q(;P7Z7JL>HB(DL!N'Q([:@B2
M1)#.^: +'-\8N S\+QL!J"S\,D2IO!A+0<C!G&D% J84XV%OXCYMKYE';KSZ
MZ6VR\?.+C97?5]]"OP]YC7\0Y%TPP%IL44PR88\>,^8W"A&]O,0/Z?%#<N\A
MF22=8%9>CZ.4(=ASQ[^]]G[MR(Y_\^7FVL^;QN-ZR^392?!^P//<V]M?_+3V
M'-\-84:%AVN,XOWQ[KT-XOG/FVN\ MMV#[V3NYBLV3'=4*B6E\(AZ;T!?,Y/
M:YMP>F&@&QA$=NP@U-5P9<<.?+:*](51^)I7=/!;$%D[.=9K&"-#>CE+31 %
MN=$41C\!J.BFPS/70XCUM4?Y=@+%7,GNK@V=[)3]_K/WYLF_)Y]AH8XGYN";
M!<]M&T0@WS+.:@7QZ D' 6XVAL<#V&^\0,N.*7@E^ 14L2$[!O/X,+48S(OY
M/:1^P$C0:4'%J1;5$*WA#VK9@]C"%,OVRPH9)9'%0%Q.AEU2Z#1:6((TLA.+
MT+22#1X45/CB"3B3)GI2304-90F,6!HE7TG%LH#0;C\3^WE=F4%OYY"[5'50
MI:N4=03L-X*%$U8H^/!/ZMWP?_0(JOJNO/010[)M0;BMCU]>(J .P./R_K7C
M0J3C489$E<UB %Q,J45N-#0E@5+?$*9RAZ5V ,#:9AM JJK<[2>WS12\<LE\
MK?F7WG!:*[J9:,8NLF&8*FO;,=:,@*N]X9[=:#OZ=CYJ\,90X["9+Y^)$D]D
M6Y5P;X@VL(6GL<KOY:6 R=Q.FOA$D%;,*#.(*HH-+"]Z1#7U$M74YZQ@MI<3
M!"*;$?_WM+INQLQ7P#>;U%*9!>%:+.A4H8^9-%9>41>V4E0A3Q)@&[!:=?69
M,=$#688R=G.0+\L>,BY<920 /"! \8!7MLC --._3?-.9#'^.:4F7/:@0TS8
MNB<!/6K)S, 8B8SQA%F_5 )M'J<BS>L118*:BOYZ\-?NT?[N_J_)7N<S"\*'
MW6-S?_UZU.U^[.Z?))W]'?._WY+MO<[NQS39/M@_.8)O'?^6'!PE.[O'AY].
MNDGG:/<8'O-I?Z=[!+\XZNYU3KH[R<D!/C%Q#SS^T-G;2[:Z";W<?&;KMQ1?
M8YY]?'+TR?QD=S_I;&\?'.UT]K>[R>?=DP_F*5T8Y'%R\#[%?QR?F!>8?R7[
MW<_);P='?\'/'7PZ,>_^M7.$K]X].4ZV/QSL;N,'S=>30S-X,U3SIN\X4/?Z
M*5!W+X?"\DX*+_9_*X+OMXE3H+N83Y^P[NQ8RZ">0HF2916?HT 4O<K7Z0^Z
MET@$T06QD JCQ@#FB0J237VH?9NT10T&DKQ'XO5);AN8;!=,K[,- 7*\U5QR
M?JNL@$@;?O@Q&QO?:))A_1&-"%U-,MSTFX\E.&%+06[[RF2E9TP,,D,0Z.F!
ML8]M^_%M'(</Q';L $3FJ2X:JH]607^QE3S:=R'G'_C;70>[0<71]EE42N;X
MPG0YFXTXXKJE7 !'&"S\N?=^(S<+0?SL\%<EX2L&"F]/H4A^ CE683KC=E*I
M$8^4YPR%E,:-&V$J6JAS'8X(KE> K5A:7%QM2S.1]?L54J#;G!@1.#F:$!O.
MK=W;)<]HV8R#0;,=J#B2*J)]US/%R9/Y8_L%*!E E+DF5Q<#A&MV,)2ILH7#
M[)I34Q89L]#06/1#6:58QR+C<=@&REL; Q?RK\X?:4PZ\7NO+;IZ%BFFGF3S
MZMX* R"B')MU*+@P?CIZ1(.'.!Q.=C]VV<XQ?W.VB+$.P*;H'A]W][?YG]IJ
M65M>ZOYMNWMH["%C@9B/'GW>/3;?[YXD[P^.C'EB?M+=W4^3X\/N]N[[7;!\
MS O 6DEV.K\9D^2]L8N,16*-E>W=D]_P,X^X)J]=^ (A&ZR6&"2+Z[2\=(*X
ME4MS/?<YXC\-/BA2;FOAH)7&F=$\YZP[V+=MNK^J61[!'>$0Z%?%7T2R.>]U
MY <3<_O7C [[RP>4T8I 4FA.<;C!L@PI9U;E+>2HR("!!\@\"XXH SM7T#<>
M#Z\COUS%F*!Y9+-MMW%]:11XF[E!/")J:W.=;:DIQD4SOG@;X0R7H^G)50G+
M[0H!>NH)T'P#;D'XDE#V>;]G5@X+A\0FB7/PD*NNI1W?L=$M@YXUQF<LQAF7
M-5'!).E -P+&Z)=G.0-!Q0J@?C."DH(<INK4I)=)EL3-Y;* ]A<];$H#8&?;
M,YONU!6O[YKNJ8WT2,+H;]?%YJ'$,NP>&W.=.(P&9N/6UU,P#W'!NNY9)]H8
MQ09Z\"#U@6-Y&5U;D.^N^K7P4-&9#3WR?.UL+4VNKJ[6P%2 X:Z9S5EU7V"(
M*_>L)#9+2<NJA4_J$F(SLF+SX;3P##PSPVNUTAR)58?)&A[284AR68^GMC<)
MAMP5OH3EI0^$M*I=*$?J(\[Y-Q)7!/TQP&@87\Q@2HUY/:+:F*._\CA2J8\V
M=<*"0LZMRE64/:I:ZBG$ ',$GL/&(0>,(EDB6PIB4DP+6;OF/D*A"')HCLAJ
M# 5I3W.\/!*]G5&S&@G//^? "9/F+>M]=K,- PE_AX/?.?ETU$T..[\::^7]
MP=[>P>=_?+>1D>?K3Y&1.T6&2!+;N*\E^BEUK+?(M?$"_*.$$8ZI.FXI^B-U
MCE<291"JW%P6#9QEYJEUX3BXPFR?C904J),8I#,$WFY"V0^'WFUL842 / $@
M9"$\NS:;@J3?<S,>D3EC9 #*CIO'5BWQICLKK4=''Q64 182C%"CC/QRTMG:
MZR;;W;V]X\/.]N[^KW_^8?T'_/=A9V='_LV2]@($;>O@:*=[A#_F4=%/GAGI
MW.L<'G??R%]FBD H+R!_=(Q.CM[Q7W;DQ3_]Z0=SWDYVW"_^RE.AR;JS(!_T
MO_]Z4WYN_N^(?GDDPU='L4 JJ#?996ENZ1L.OV5@9C',RN[#,7[W5R0+J,!*
M ,&N4S<D-_G(7JO'?^CN_OKAQ$STE?_HAYT<5']XK^_N=7?,+7KXH7/TL;/=
M_72RN]W9.TZ3W?WMM;:AS9V@MY/1B6\^QL3?;5V_T2,+=YP'P ?EV=;!R<G!
M1S/'+Y =-2/XPSK^]]:=SN:S<(']XS7C.3_6/R8[V671?]89YE^,BC&VV/9:
M\FM5&D7U<6VG=0ON<9%FK-"<>;_;-S[,FW^G"2%XY4VR?5[D@Z1+#'[&\.?6
MZEH)F#] (;\C$R.Y$\W_I.8?6,UO'^R_WSWZV-VA%.<V1/>Z.[-T_0-IZ?_Z
MP\\;KU^^[=B,"39H&Q058(\Q+L[>R9NOUMG?TJ6TU^T>[>[_Q7@@1R?[W:/C
M9&]O^^DR>IC+:)SL3$\!ROC]:6NY?K[C*?"%\^NP/,V&QM=X]@$S-L"Q#73)
MZ*!L$=->[/:Y80#FQJAMX^'D!/^!R'-(IS!0%9V>[P1$W_T;$GU_OUB,OQ__
M<ORQL[?W3B(IO_Q(_UY>.N3?='ZU/TSX1R<']B>?^$< G/E\M'MB;GG[NP[_
M3K)0\HM_/$4Y[G +C[<_='<^&<.K<^\!..Q&%2_^OH",UGFF4T9_W%A[]=)5
M.[=^;6[^_[#*G[V'^$Q?<O_,7*^ C?"R%Z^_*K3[%2O I?;AU)D3"9"CG*B(
MU9-[*_3RY4;*K76AWIGHO/)_0=]UK]--N' 6:["\1$854M3]<7UM_?5K-Z(
MY(_ON^6:WVZT27RP-2X?AN"&UUP=;03YJP<9$#2G7M56'_JB,5-T(R[FM\
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MDCWD"NT1)MIH];6&R%977EN]"+77F$#%M9::0[Y$%UZ4E%/5$SE)N@36[KU
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M@#Y0LS)I.%P&F3>?5@:%[Q&(M/F?@/#Y]] I&QM1I=*N&(R!M+F:W,V1T ?
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M-,*(!EM>BJDPG,HZ3"5EU(>TII9[2W#=T:)GY/X$2ZAY\84<?9EWC5,P),+
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MYD=)_*AY.4BN6?!JG%_/NB2".//+E6PU512B5JMZU%D89[E4-J$0*[AU5K5
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M<&"Z*RM2UL5*  V%'Y6/M]#O^_@*X\!7&$EN6W/22G9'4"9-FPK6%&PX.\&
M4*;$@^HW.3XB;YW[T1TP61:/L$7M A+TT\TQ+OQ(B\=0#R0E$EZ(ND>^7./L
MHUPJ@17 TJ&-F:'+C%V8<#G^EL .BT].1*?>S_O/L5<7VSA"^#@#)0M(GWF1
M'"LYNK"OR6TR0F:%,L(Z"<GS1OZ0FV0&-%S,RPK%D;X$B:P P>A] V<T'R9R
M_^\Y,*D(J+::XP:0=Q>N29-XD*1)M4!''SD*Y$IR^-DO)SGPFXP=0>3Z!&I1
MV9#T;%"O<=AEPG2.]-V+C/I!/F?6V&&&'V"*W<Z&U6TO8$YL9AE/)"R&R .\
M0WE6C*5"CS%[RH7V<FN* )5Z7A"A% JIB<:"XCQG#BJ\HV]8WTK%#>D2M]$H
M_&TG1YA&!KL]3(KA?%H*FRS$@VPXX!UPQ#)7L,H\L4*A6$%F-\^(8H(G6\?K
M?=RE3*W]56[CT "I<PQK?#PZ$QL2$SO42KUO@U^'1FR<EG3JC#;7;L[2WA-/
M'RS(4RK:CJR#-B.Z'?TL[:=)7(7,H\B &B66@TRS30)Y#NU_ST$(DQ=K@ H&
M&[#$(I P5I+I/S;V-P]ZQI+]6^^?>/_&?@\8,.[U;FWS[$9@,#1PL]0V\HDX
M1"A>B('R_8/38_VH@_/+H^/+S</ST]/]BZOC7?W'TMT-2>%)Q(_YY<GVD^CP
M^/3T8O_HZ.3L5_/YZF+_4']V/4X\GDOV346_1$\<EU9"G'XWOLV3D5QXI&]^
M^8.=U/51\..//SR)_BJN+%@4X]9B#Q6L*Q+$]LZK7]Q[W6N\N]T0:^0O=?2I
M,=9743 XM/"-VKL;;22B!"*5_?6W_0NMH[A*83(%PQ+DAP++;(:D.PH="&UV
M<+=CS1#AJ<T6BE%&89XWUI>#BJ(U7EQ/;\U%*PH5^P%&\8)C&?!H% :Q-Q\X
M[DBIM#GPKTO\%U(L[E3T>M;B7*QM1.3NQ$_!*?CL( T-+'@6R:G[3_;X_F?P
ME)V=1J;2SAA 07K6BQ[F2+@'P-.3\YDB]0(N-+&(R3R-"W2]T2TW.;Q%R[@-
M/YA*08D?M[<W!KV-'W\B-^<EW4[J\]F[*XSL-H4KQ@J5[-2)=D1I?%?V<+3$
M*)P!]X%/:4855S)JU\QC60OV2$*JYL;BLW(UQZ$.[_H?YUT'H)]=%)KWB8%B
M-3(9!5R1#9,93%Z/YUU<?%"51#=!"V4!?Y#F.6H'D^ATZV(+?]5^%O*UNU,W
M+E&F$V=IED]@.5<V1#>:DRMF'?I 8NMVW(5&BO6<4-K-=9='0-^\>O0,!V8!
M.YX-T_F(%5_R\]4OM^&%89JS9;#N$%U2Z*UYC'!029O %**I>9::%[WFYFG>
M /_8,CBG]>)/YA-_?#EQ5-ZFOXH:I.MW]?)!U,N#KUB]K*-O&CR!I=B:$N<B
MF?"*"+99+?MNF#P0Y?SM*Z><5F.8=/F[?)Z.T)*V8)*9"T@, Q?H^2<L"7E:
M4.A8H"-%NORKA1&;Q]T!:08. +3\[05%;'V#<3VXN-5F9#RBB\1Z;D SZ79"
MKPW/K6]<4".#5F'?TDA5%(NW**)Q4I255BVL'WZ8QO-2[Q,)/X07@VAA2DT,
MI-#J0@E)^RQ*DU*\ENCD8"=Y'"A&/*8!*%>.'SIXGHXZDVX$6__ON2K%A5NP
M4,X4TE+E*'LXWUZH&XHNY@77UAOY<O5M8T!!GIHR3H#1GW>?;T?QUA0NP^W[
M>UY\B [178K3(4_HB]WM9]&L[8H>J,B#'A+Q^?7A_SG 0>$??R.TEV\!NTMZ
MFZ?S*9(Z D%P!J M !M:L<QT3DA[V9!%7[*T_G@BS_\ @QXN)Q'!WC8L-NVW
M3*GA->A=AF?21$I#'-[C8\:;9';3X"=TN5X@[O <S")-"^3IC@A5$B,081)G
M$C(GUS$[P&%5ADJ,B)P@V>-Y-JQT$(M?@K_RF'J\ ].\K,@=""S($KCGU*T-
MO,S-D,EWO3'2BYBA/QMX&S$FC$V7?8DX)04R%YP,PW:)GS7[C<G <P\^\#=D
M0#-%7 CWKXB!P2'&.U4$68,73_(<L3?(9857L&4BK',:_YX72*X)/@R>KBP?
MT8!&W@TWUHLZ ?O%@5Q,?!%9OQ__H5EV.V.E&,*N/L)@)4K-I]BX827JXH7!
M_TBBPP/QY39;L,:EE_&H!E,3(Z9% N.&]YO#D]'BU ]07Q;)6IB"(K4H2VL3
M^_!ZPC3%Y2C^MX8FR^"^0$# P?0[D(GZ2J*HNU/J WH)/3;?:I@3)\*<+5A,
M])>XB_=53+2-: 0CYTMK9@0EL@X-ARV7R[MEW!?8C6,!.Y)WEXGC[U?'T?Y4
M 5^+LWX[O7@__9KF@Z6_7!'G,>> N;N1BSSN8PWUW1#UACAT6>;H:,C]I0$#
M-X>Y2!CK6_0#/___P0_\>,A?>\30R?-@.C/F6GPFI;GU9.GP-FL%#*SU':^:
M"_3E'*/,>&#5$-W C6IWZY#7&6Z@37Z-.CM,_+Y*>SUJ]4WJ[-W._97V:(7.
MKO?1[%GR-:KL#?K8"IT]^D]1V1E'N[;.'GTS*OM)'2,H>4V"&:<3UN '$N&
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M#?SATT;9C:94Q2#//VS"UA8+3E]?2XALL;JYKEH9YE&PE<J5L4C1U(E.*"]
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MF10:X(%)AJI(N6U<Z-*W5A#OCYL?7C>+PITB(F,?@"ESYR2]U9,#T#WWS?E
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M')^/T.5Q_@9&F[H5OA5 >%'_U:A?OS/ PC(N*PJ;""PH\P>L<E8Y]55]_66
M_1"&I%5P&9)IG*38N817N)Z_&_8+M'!H!U&LG1'L,"""]5;%I\NP90]R/N^]
M<30HL+"L:0MJ:M>@QJA+1QAKQ+[KBQ?GE+I\EE[WT6[R.E6Y%'PR;DP6UX)
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M"]S8@_/+H^-+^EI&Q=]L C6<[E]<'>_J/Y8N>;@_N-],MM>7>_+'D2&I9S_
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M4;6^-H]=CWD),L POVJ1,ZBE'^FS^\SX0[@!V8P63@3^G)A0<LV&7,76CO:
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M,N5@K3G"8]Z#7N ="BBN!E3'"V5CCH3*X@Y@&E)%GP!J#*]](UB^\!(DKT*
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M(6:;4]S=#*>]O6JW#?W\#5!+ P04    " #PIFQ;D]9]N7\&  "X1@  %0
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MDEPU[=<-R5L2K@1-MN>;<*[\DD_!@MB2:<[M"-!:([PZQ@77:CTD:HL"4%0
M7<*9W?;Z+B/<M'DWD$\7ZO5:_4DNXF!F2_"CI([0-;?.#0==8#4((5'Z31FT
MM#.=+31:QM*V6S<<SUFBT!^K,B*(+]65Q.9WLK7%LB*Y(SSKK?":(!=<:P21
ML,TJ0%X"TAJ@BC@#W&+K99";]^^&]!D/5WIN)JI[6Y)W<SH"V-@XWS_F@NN^
M#A*EA3!H96<T\=LL$VG9*PZ&-T10'IVSZ$R],6_*XZ/DCL$T6^$U01BH&@2Q
MF<U*@*H!N@@:OBVT;N38NG^,BX7/9$;UNSV6-'D39L[M]%*AP@BOCG&_4##I
MX5XG/%3 >1/67M^&BP3KYC% OF0A%TLNTGM^MXD:G#%?J8N4[9A'#;D^(-4I
MYG8VN76*^Q!8R./.Q$Y!2"M"7A)T3:0A^0Z^##/S=',80W1!8_)IM9@2T6QB
MRGF=CH?! #<?=P?_L18NY5H=,GDDH+'[-=!KU30&J)-@<QFIBR5Z1[.G/$^A
MME*D4X0/6>,6P>YPUPKCDJY*P6XM7.Y;M6(8@B?XP1B)TRA2!F3^SQ5E9-AL
M'(P"G8Y"G25^(-!]!"I%<?'/]5\5&Z KP37#NHYIS88!_2=X:0=]WQ5]_]FA
M[]NB[[>!OO_]T)^L>6OH(]FP1K_6"R+Z8[5Y+29\S9X$?CG].6!OL&."_B$,
M#?G'DBT!K\L %Z +X<*.;: .=3L7B)BG[X>OQ8W@]Y2%#6_K5&D\!^"KC)FH
M?Q2+AKY1MR7^LQL;"IVB&NX0M&*E;A(:^$$<AQLNDR#^FRZ;W^,T*SR'43";
M,@W"3B3:&!A46QJ"K!*H4ICW+=NS43< UEX</\RJ#0H2- %^-Z>KC[*:&N?[
MQYP^R+JG@P1N^O^\5L;A%+_/G0^Q6C;K!J+^='E\,^>LX?WR_;R.@*PTP,W'
M7< T:R'!F8I#JHYUW["=?LN0-FG:#=0_!4T2PL9\L5BQ_'ZDM*6U(KDC9.NM
M\)H@%WAK!)$(SBO ;@EGBEMLO(QRT^X=EP[PF(8TH6SV45UQ"QK$MBR;,KM:
M-E!M@E=%."T9J%!#XO=!'@I]]]4"+;6\LU:@2=]NV-X(HN>#*"S23T+J95[B
M^N[._L*A3J$CC"U,\4.1+E@?4D7"6Y6!<AW("D%:R1GTMDV4@7^B$U3T+Z5<
M$>$^  :=YS$&U0;-P[ 7CS@2%=IM#496KM7Y:,E1[90TLH6S,G+H3R<TB1NO
MBGS(ZWA%Y)X!;CZ.L1)R5POKHJ982*C4(95'6P&)VZ]Q]:-%TVZ@3D2@OS+A
M=KN8<NM+\$=)'2%J;IT;#KK :1!"(C-7ADS:F<H6&BTC:=LMQF.1\P41,U7L
M@^#K9*Y>PY<!:[C^L4*BTP<C];;XP5#W1R,ULKC/1HI"D%6"O!32HY$6;1B>
MC=AZ*>^X4EOZ*U?R733[XA&UYW]02P,$%     @ \*9L6W(2(C[%!   .BP
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M  !D,C@W.#5D97@Q,2YH=&U02P$"% ,4    " #PIFQ;8V0-SKL^  "F)@$
M#P              @ &EZ0  9#(X-S@U9&5X-#$N:'1M4$L! A0#%     @
M\*9L6V1C'6Y&#P  4D@   \              ( !C2@! &0R.#<X-61E>#4Q
M+FAT;5!+ 0(4 Q0    ( /"F;%O/1+)Q.P,  $4+   1              "
M 0 X 0!E;&1N+3(P,C4Q,3$R+GAS9%!+ 0(4 Q0    ( /"F;%N3UGVY?P8
M +A&   5              "  6H[ 0!E;&1N+3(P,C4Q,3$R7VQA8BYX;6Q0
M2P$"% ,4    " #PIFQ;<A(B/L4$   Z+   %0              @ $<0@$
K96QD;BTR,#(U,3$Q,E]P<F4N>&UL4$L%!@     '  < MP$  !1' 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>d28785d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eldn-20251112.xsd" xlink:type="simple"/>
    <context id="duration_2025-11-12_to_2025-11-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <startDate>2025-11-12</startDate>
            <endDate>2025-11-12</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2025-11-12_to_2025-11-12"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-312">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-11-12_to_2025-11-12"
      id="Hidden_dei_EntityCentralIndexKey">0001404281</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-323">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-324">2025-11-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-325">Eledon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-326">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-327">001-36620</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-328">20-1000967</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-329">19800 MacArthur Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-330">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-331">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-332">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-333">92612</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-334">(949)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-335">238-8090</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-336">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-337">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-338">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-339">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-340">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-341">ELDN</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-11-12_to_2025-11-12" id="ixv-342">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
